Methods for the Storage of Whole Blood, and Compositions Thereof

ABSTRACT

Methods and compositions for improved clinical outcomes for trauma patients receiving whole blood transfusion. Methods and compositions for improved clinical outcomes for blood transfusions for cancer patients are also provided.

FIELD OF THE INVENTION

The present disclosure relates to methods for improving the quality ofwhole blood useful for transfusion to patients. Anaerobic storage ofwhole blood provides for reduced levels of cytokines and improved levelsof 2,3-diphosphoglycerate (2,3-DPG) and adenosine triphosphate (ATP).The improved blood compositions are useful for blood transfusions tocancer and trauma patients.

BACKGROUND OF THE INVENTION

When stored conventionally, stored blood undergoes a steadydeterioration which is associated with various storage lesionsincluding, among others, hemolysis, hemoglobin degradation, and reducedATP and 2,3-DPG concentrations. When transfused into a patient, theeffects of the steady deterioration during storage manifest, forexample, as a reduction in the 24-hour in vivo recovery. Because ofthese and other medical sequelae of transfusion of stored blood, avariety of approaches have been developed to minimize the effects ofstorage on blood and to improve medical outcomes. See, for example,Zimring et al., “Established and theoretical factors to consider inassessing the red cell storage lesion” in Blood, 125:2185-90 (2015).

A number of approaches have been developed aimed at minimizing storagelesions and improving transfusion outcomes. One approach has been thedevelopment of additive solutions included during storage. Examples ofthis approach include U.S. Pat. No. 4,769,318 to Hamasaki et al. andU.S. Pat. No. 4,880,786 to Sasakawa et al. which are directed toadditive solutions for blood preservation and activation. For example,Rejuvesol® (available from Citra Lab LLC, Braintree, Mass.) is added toblood after cold storage (i.e., 4° C.) just prior to transfusion orprior to freezing (i.e., at −80° C. with glycerol) for extended storage.U.S. Pat. No. 6,447,987 to Hess et al. is directed to additive solutionsfor the refrigerated storage of human red blood cells. An alternativeapproach is to freeze the blood and prevent the development of storagelesions. Storage of frozen blood is known in the art, but such frozenblood has limitations. U.S. Pat. No. 6,413,713 to Serebrennikov isdirected to a method of storing blood at temperatures below 0° C. SeeChaplin et al., “Blood Cells for Transfusion,” Blood, 59: 1118-20(1982), and Valeri et al., “The survival, function, and hemolysis ofhuman RBCs stored at 4 degrees C. in additive solution (AS-1, AS-3, orAS-5) for 42 days and then biochemically modified, frozen, thawed,washed, and stored at 4 degrees C. in sodium chloride and glucosesolution for 24 hours,” Transfusion, 40:1341-5 (2000). Another approachrelates to the containers for blood storage as provided by U.S. Pat. No.4,837,047 to Sato et al.

One approach that has proven successful in improving blood quality andextending its utility is through the depletion of oxygen and storageunder anaerobic conditions. U.S. Pat. No. 5,624,794 to Bitensky et al.,U.S. Pat. No. 6,162,396 to Bitensky et al., and U.S. Pat. No. 5,476,764to Bitensky are directed to the storage of red blood cells underoxygen-depleted conditions. U.S. Pat. No. 5,789,151 to Bitensky et al.is directed to blood storage additive solutions. Among the benefits ofstoring blood under oxygen depleted conditions are improved levels ofATP and 2,3-DPG, and reduced hemolysis. Storing blood under oxygendepleted conditions can also result in reduced microparticle levels,reductions in the loss of deformability, reduced lipid and proteinoxidation and higher post transfusion survival when compared to bloodstored under conventional conditions.

U.S. Pat. No. 6,162,396 to Bitensky et al. (the '396 patent) disclosesanaerobic storage bags for blood storage that comprise an oxygenimpermeable outer layer, a red blood cell (RBC) compatible inner layerthat is permeable to oxygen having an oxygen scrubber placed between theinner and outer layers.

While the effects of oxygen depletion on packed red blood cells has beenexplored, the effects of oxygen depletion on whole blood has not beenreported. In part, the lack of studies on the deoxygenation of wholeblood may be due to the expectation that deleterious effects areexpected when platelets are deprived of oxygen. More specifically, giventhe critical role of platelets in the coagulation process, there wereconcerns that decreases in platelet function would result incoagulopathies and negative consequences to clinical outcomes.

Storage of platelets has been extensively studied to identify the mostfavorable conditions including temperature, pH, O₂ and CO₂concentrations. The result of this work is the conclusion that forstored platelets to persist in a recipient after transfusion, plateletsrequire access to oxygen and storage at room temperature. Murphy andGardner noted in 1975 that unwanted morphological changes wereassociated with reduced oxygen consumption. See, Murphy et al.,“Platelet storage at 22 degrees C.: role of gas transport across plasticcontainers in maintenance of viability,” Blood 46(2):209-218 (1975). Theauthors observed that increased access to oxygen allows for aerobicmetabolism (oxidative phosphorylation) resulting in a reduced rate oflactate production. At low PO₂ levels lactic acid production isincreased consistent with the Pasteur effect. Moroff et al. noted thatcontinuous oxygen consumption is required to maintain the pH of storedplatelets at pH 7. See Moroff et al., “Factors Influencing Changes in pHduring Storage of Platelet Concentrates at 20-24° C.,” Vox Sanguinis42(1):33-45 (1982). Specially tailored container systems allowpermeability to carbon dioxide as well as oxygen to prevent a lethaldrop in pH. As shown by Kakaiya et al., “Platelet preservation in largecontainers,” Vox Sanguinis 46(2):111-118 (1984), maintaining plateletquality was the result of improved gas exchange conditions obtained withincreased surface area available for gas exchange. The importance ofmaintaining oxygen levels during platelet storage led to the developmentof gas permeable containers and storage of platelets in oxygen enrichedatmospheres. See U.S. Pat. No. 4,455,299, issued Jun. 19, 1984, toGrode. The importance of oxygen to the viability of stored platelets wasreinforced by the observation that in an oxygen poor environment, thelactate levels increased 5-8 fold. See Kilkson et al., “Plateletmetabolism during storage of platelet concentrates at 22 degrees C.,”Blood 64(2):406-14 (1984). Wallvik et al., “Platelet Concentrates Storedat 22° C. Need Oxygen The Significance of Plastics in PlateletPreservation,” Vox Sanguinis 45(4):303-311 (1983), reported thatmaintaining oxygen during the first five days of storage was criticalfor platelet preservation. Wallvik and co-workers also showed that themaximum platelet number that can be successfully stored for five days ispredictable based on the determination of the oxygen diffusion capacityof the storage bag. See Wallvik et al, “The platelet storage capabilityof different plastic containers,” Vox Sanguinis 58(1):40-4 (1990). Byproviding blood bags with adequate gas exchange properties, pH ismaintained, the loss of ATP and the release of alpha-granular plateletFactor 4 (PF4) was prevented. Each of the foregoing references arehereby incorporated in their entireties.

These findings, among others, led to practice standardization ensuringthe oxygenation of platelets during room temperature storage to maximizepost-transfusion viability. When platelets are stored at refrigeratedtemperature, post-transfusion viability is lost, making such plateletsunsuitable for prophylactic transfusion to oncology patients unable toproduce their own platelets. On the other hand, platelets stored atrefrigerated temperature maintain hemostatic functions when transfusedto recipient. Thus, when giving platelets to patients suffering fromtraumatic bleeding, viability is less important than hemostaticactivity. We demonstrate that anaerobic storage of refrigerated wholeblood up to 3 weeks yields hemostatic activity consistent withrefrigerated conventionally stored whole blood, clearly indicating thathemostatic activity of platelets is maintained with hypothermic storage,even though they are oxygen starved.

Though the depletion of oxygen in whole blood has been mentioned in theliterature, the effects of anaerobic storage of whole blood has not beendisclosed. As discussed above, it is well established that roomtemperature storage as well as oxygen is required during storage forlong-term survival of platelets (PLT) (more than 24 hours) inrecipients. However, for hemorrhagic trauma resuscitation, the long-termsurvival of PLT is not critical compared to its hemostatic potential.Recently, it became apparent that patients transfused with stored orfresh whole blood, as well as reconstituted whole blood (a mixture ofplasma, red blood cells and platelets), have significantly lowerpost-trauma mortality. We recently discovered that cold storage enablesanaerobic storage of PLT and also provides known advantages ofanaerobically stored RBCs observed in packed red blood cells, in thewhole blood. More specifically, while unexpectedly preserving thecoagulability without introducing negative effects, deoxygenated wholeblood provides for improved 2,3,-DPG levels. Over a storage period, thedeformability of RBCs is maintained under deoxygenated conditions.

Oxidative damage during storage has been implicated as a majorcontributor to packed red blood cell (pRBC) membrane damage, assuggested by the accumulation of markers of lipid peroxidation, such asisoprostane. Increasing amounts of cytokines during storage duration mayalso play a role in storage lesion development with potential clinicalimplications for a negative transfusion outcome.

Certain patient populations are more susceptible to storage lesions thanothers. Among these more sensitive populations are, as non-limitingexamples, trauma patients and cancer patients. Associated with theadverse clinical outcomes is the accumulation of biologic responsemodifiers (BRMs) that include cytokines that mediate inflammation,regulate cell growth, regulate angiogenesis and modulate t-helper cellfunction. Among these BRMs are interleukin 17 (IL-17), eotaxin (CCL11),basic FGF (bFGF), macrophage inflammatory protein 1a (MIP-1a), monocytechemotactic protein 1 (MCP-1), platelet-derived growth factor (PDGF),tumor necrosis factor alpha (TNF-α), and vascular endothelial growthfactor (VEGF). See Behrens et al., “Accumulation of biologic responsemodifiers during red blood cell cold storage,” Transfusion49(Suppl3):10A (2009). It has also been observed that cytokinesaccumulate during blood storage and these accumulated cytokines can beassociated with negative outcomes when given perioperatively to cancerpatients. See Benson et al., “Accumulation of Pro-Cancer Cytokines inthe Plasma Fraction of Stored Packed Red Cells,” J Gastrointest Surg.16:460-468 (2012). There is a need for methods of blood storage thatresult in reduced levels of BRMs and cytokines, thereby improvingpatient outcomes.

Traumatic injury accounts for 30% of life years lost in the US,outpacing cancer (16% of life years) and heart disease (12%). Trauma isthe leading cause of death among 1-46 year old patients. While deathfrom hemorrhage often occurs within 24 hours of traumatic injury, earlydeath (within 3-6 hours) due to massive hemorrhage is preventable withprompt and appropriate care.

Damage Control Resuscitation (DCR) protocols describe the concept ofusing balanced ratios of blood components. DCR is rapidly becoming astandard for arresting hemorrhage and reversing shock for rapidlyhemorrhaging trauma victims. In the civilian setting, current bloodbanking practice does not include whole blood inventory and thus DCR isconducted with a sequential transfusion of separated components (RBC,plasma and platelets) such that blood is ‘reconstituted’ in therecipient. Earlier this year, a large scale randomized controlled trial(RCT), Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR),was completed comparing the efficacy of transfusing ‘reconstitutedblood’ at a 1:1:1 unit ratio (plasma, platelets and RBC) vs. a 1:1:2ratio to trauma patients with massive transfusion. In major traumacenters, massive transfusion kits combining pre-packaged blood productsconsisting of thawed fresh frozen plasma (FFP), platelets and RBC at1:1:1 ratios are now readily available.

Recent studies suggest that whole blood may be superior when treatingpatients with severe bleeding to control hemorrhage and reverse shockfor patients with life-threatening bleeding. The 2015 proceedings of theNHLBI State of the Science in Transfusion Medicine Symposium prioritizedthe study of whole blood for patients with severe bleeding. Likewise,the THOR Network, an international group focused on damage controlresuscitation, has prioritized the comparison of the efficacy and safetyof whole blood to components for hemorrhagic shock. Since modern bloodbanks do not routinely supply whole blood, over 80% of level 1 traumacenters surveyed attempt to mimic the hemostatic, shock-reversingproperties needed in massive transfusion protocols with plasma,platelets and red blood cells units at ratios of 1:1:1 to 1:1:2 for bothtraumatic and non-traumatic life-threatening bleeding cases.Logistically providing all three blood components rapidly and safely isdifficult, especially given the need to thaw plasma at centers where aninventory of thawed plasma is not immediately available. Recent dataalso indicates that storage of whole blood at 4° C. for up to 14 daysmaintains platelet function and global hemostatic efficacy that issuperior to storage at 22° C.

In addition to a need for blood banks to provide whole blood for use incertain patient populations, the ability to conserve valuable bloodresources is important. In particular, blood banks typically discardwhole blood stocks after 2 weeks (even though FDA regulations allow forlonger usable lifetimes), thus failing to take advantage of a valuableand often scarce resource. Such ability to maximize the value of theblood resource is particularly useful for small hospitals that serve asLevel III and Level IV trauma centers where an oxygen depletedhemostatic whole blood product can be maintained under anaerobicconditions and then processed for packed red blood cells. The presentspecification provides for improved whole blood quality for use intrauma patients, and further provides for an additional source of packedred blood cells having improved properties and reduced storage lesions.The present specification overcomes concerns regarding the wasting ofvaluable O-negative RBCS (typically used for whole blood transfusions).Thus, the anaerobic RBCs may be obtained from the oxygen reduced wholeblood and recycled into oxygen depleted RBC units suitable for storagefor up to six weeks. As provided herein, deoxygenated packed red bloodcells may be obtained from the unused oxygen depleted whole blood, usedfor transfusion, or stored for later use under anaerobic conditions.

SUMMARY OF THE INVENTION

The present disclosure provides for, and includes, a method forimproving survival of a patient in need of multiple transfusionscomprising providing stored red blood cells that have been oxygenreduced to a patient in need thereof receiving a medical procedure.

The present disclosure provides for, and includes, a method forimproving survival of a cancer patient in need thereof following aperioperative blood transfusion comprising providing stored red bloodcells that have been oxygen reduced to a cancer patient in need thereofreceiving a surgical procedure.

The present disclosure provides for, and includes, a method for reducingpro-cancer cytokines in stored blood comprising depleting oxygen fromthe blood prior to storage comprising collecting blood in ananticoagulant solution, reducing the leukocytes from the collectedblood, reducing the pre-storage oxygen saturation (SO₂) to 30% or lessand a pre-storage partial pressure of carbon dioxide to less than 60mmHg; and storing the oxygen and carbon dioxide reduced blood underanaerobic conditions.

The present disclosure provides for, and includes, a blood compositionfor transfusion to a trauma patient in need thereof comprisingdeoxygenated leukoreduced whole blood in an anticoagulant solution andhaving a pre-storage oxygen saturation (SO₂) of 20% or less and apre-storage partial pressure of carbon dioxide of less than 60 mmHgwherein the deoxygenated leukoreduced whole blood has a 2,3-DPG level at15 days that is greater than the initial 2,3-DPG level of thedeoxygenated leukoreduced blood.

The present disclosure provides for, and includes, a method of reducingan inflammatory response in a patient receiving a blood transfusioncomprising transfusing an oxygen depleted blood product to a patient inneed thereof, wherein the oxygen depleted whole blood has reduced levelsof inflammatory cytokines after storage under anaerobic conditions.

The present disclosure provides for, and includes, a method of reducingan immune response in a patient receiving a blood transfusion comprisingtransfusing an oxygen depleted blood product to a patient in needthereof, wherein the oxygen depleted blood product has reduced levels ofa cytokine after storage under anaerobic conditions. In aspectsaccording to the present disclosure, an immune response is an immunemodulation or immune suppression. In other aspects, the immune responseis an activation, including for example, inflammation.

The present disclosure provides for, and includes, a method forimproving perfusion of oxygen in a patient in need thereof comprisingtransfusing an oxygen depleted blood product to a patient in needthereof, wherein the oxygen depleted blood product has higher RBCdeformability compared to a conventionally stored blood product.

The present disclosure provides for, and includes, a method for managinga blood bank comprising maintaining an inventory of blood unitscomprising oxygen reduced whole blood and an anticoagulant, or oxygenreduced leukoreduced whole blood and an anticoagulant; providing one ormore of the blood units from the inventory for treatment of a patient;and recycling blood units from the inventory to prepare componentseparated deoxygenated blood units. The present disclosure furtherprovides for using recycled blood units to prepare reconstituted bloodunits for treatment of trauma patients requiring massive transfusions.

The present disclosure provides for, and includes, a method of providinga supply of blood products for transfusion medicine comprising depletingoxygen or oxygen and carbon dioxide from whole blood to prepare oxygenor oxygen and carbon dioxide reduced whole blood; and storing the oxygenor oxygen and carbon dioxide reduced whole blood for a time period andproviding the stored blood to a patient in need thereof; or storing theoxygen or oxygen and carbon dioxide reduced whole blood for a timeperiod, and preparing oxygen or oxygen and carbon dioxide reduced packedred blood cells.

BRIEF DESCRIPTION OF THE DRAWINGS

The present disclosure is disclosed with reference to the accompanyingdrawings, wherein:

FIGS. 1A to 1D are graphs displaying the results of cytokinemeasurements showing reduced levels of eotaxin (1A) and RANTES (1B) inanaerobically stored packed red blood cells. FIG. 1C shows reducedlevels of cell free hemoglobin compared to aerobically stored packed redblood cells. FIG. 1D shows reduced levels of isoprostane inanaerobically stored packed red blood cells. Dashed lines=aerobicallystored blood; Solid lines=anaerobically stored blood.

FIGS. 2A to 2G are graphs presenting the results of two experimentsaccording to the present disclosure comparing the storage ofleukoreduced whole blood collected in anticoagulant solution CPD(LRWB/CPD) under oxygen reduced, oxygen and carbon dioxide reduced andconventionally stored LRWB/CPD over a period of 21 days. FIG. 2Apresents the levels 2,3-DPG. FIG. 2B presents the levels of ATP. FIG. 2Cpresents the pH. FIG. 2D presents the platelet count. FIG. 2E presentspotassium levels. FIG. 2F presents the data of FIG. 2A re-plottedrelative to the levels of 2,3-DPG at day 0 (T₀). FIG. 2G presents thedata of FIG. 2B re-plotted relative to the levels of ATP at day 0 (T₀).Key: sample c68/80 is conventionally stored blood having an initialoxygen saturation of 68% and a partial pressure of CO₂ of 80 mmHg;sample c50/94 is conventionally stored blood having an initial oxygensaturation of 50% and a partial pressure of CO₂ of 94 mmHg; samplesc91/75 is conventionally stored blood having an initial oxygensaturation of 91% and a partial pressure of CO₂ of 75 mmHg; samplesc69/87 is conventionally stored blood having an initial oxygensaturation of 69% and a partial pressure of CO₂ of 87 mmHg; sampletc5/78 is oxygen depleted, anaerobically stored blood having an initialoxygen saturation of 5% and a partial pressure of CO₂ of 78 mmHg; sampletc7/64 is oxygen depleted, anaerobically stored blood having an initialoxygen saturation of 7% and a partial pressure of CO₂ of 64 mmHg; sampleT5/28 is oxygen and carbon dioxide depleted, anaerobically stored bloodhaving an initial oxygen saturation of 5% and a partial pressure of CO₂of 28 mmHg; sample T4/26 is oxygen and carbon dioxide depleted,anaerobically stored blood having an initial oxygen saturation of 4% anda partial pressure of CO₂ of 26 mmHg.

FIGS. 3A to 3D are graphs presenting the results of two experimentsaccording to the present disclosure comparing the storage ofleukoreduced whole blood collected in anticoagulant solution CPDA1(LRWB/CPDA1) under oxygen reduced, oxygen and carbon dioxide reduced andconventionally stored LRWB/CPDA1 over a period of 21 days. FIG. 3Apresents the levels 2,3-DPG. FIG. 3B presents the levels of ATP. FIG. 3Cpresents the data of FIG. 3A re-plotted relative to the levels of2,3-DPG at day 0 (T₀). FIG. 3D presents the data of FIG. 3B re-plottedrelative to the levels of ATP at day 0 (T₀). Key: sample c32/98 isconventionally stored blood having an initial oxygen saturation of 32%and a partial pressure of CO₂ of 98 mmHg; sample c56/86 isconventionally stored blood having an initial oxygen saturation of 56%and a partial pressure of CO₂ of 86 mmHg; sample sc59/95 isconventionally stored blood having an initial oxygen saturation of 59%and a partial pressure of CO₂ of 95 mmHg; sample sc82/84 isconventionally stored blood having an initial oxygen saturation of 82%and a partial pressure of CO₂ of 84 mmHg; sample tc7/80 is oxygendepleted, anaerobically stored blood having an initial oxygen saturationof 7% and a partial pressure of CO₂ of 80 mmHg; sample tc6/77 is oxygendepleted, anaerobically stored blood having an initial oxygen saturationof 6% and a partial pressure of CO₂ of 77 mmHg; sample T5/28 is oxygenand carbon dioxide depleted, anaerobically stored blood having aninitial oxygen saturation of 5% and a partial pressure of CO₂ of 28mmHg; sample T7/23 is oxygen and carbon dioxide depleted, anaerobicallystored blood having an initial oxygen saturation of 7% and a partialpressure of CO₂ of 23 mmHg.

FIGS. 4A to 4C are graphs presenting the results of experimentsaccording to the present disclosure comparing the storage ofleukoreduced whole blood collected in anticoagulant solution CPDA1(LRWB/CPDA1) under oxygen reduced (OR), oxygen and carbon dioxidereduced (OCR) and conventionally stored LRWB/CPDA1 over a period of 21days. FIG. 4A presents the levels of ATP in OR-LRWB/CPDA1,OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1. FIG. 4B presentsthe levels of 2,3-DPG in OR-LRWB/CPDA1, OCR-LRWB/CPDA1 andconventionally stored LRWB/CPDA1. FIG. 4C presents the percent hemolysisin OR-LRWB/CPDA1, OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1.In graphs presented in FIGS. 4A to 4C, small dashed lines=OR-LRWB/CPDA1stored blood, dashed lines=ORC-LRWB/CPDA1 stored blood, and solidlines=conventionally stored blood.

FIGS. 5A to 5D are graphs presenting the results of experimentsaccording to the present disclosure comparing the storage ofleukoreduced whole blood collected in anticoagulant solution CPDA1(LRWB/CPDA1) under oxygen and carbon dioxide reduced and conventionallystored LRWB/CPDA1 over a period of 21 days. FIG. 5A presents activatedPartial Thrombin Time in seconds (aPTT) in OCR-LRWB/CPDA1 andconventionally stored LRWB/CPDA1. FIG. 5B presents prothrombin time inseconds (PT) in OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1.FIG. 5C presents the levels of Fibrinogen in OCR-LRWB/CPDA1 andconventionally stored LRWB/CPDA1. FIG. 5D presents the levels of D-dimerin OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1. In graphspresenting plasma coagulation parameters, dashed lines=ORC-LRWB/CPDA1stored blood, and solid lines=conventionally stored blood.

FIGS. 6A to 6E are graphs presenting the results of experimentsaccording to the present disclosure comparing the storage ofleukoreduced whole blood collected in anticoagulant solution CPDA1(LRWB/CPDA1) under oxygen and carbon dioxide reduced and conventionallystored LRWB/CPDA1 over a period of 21 days. FIG. 6A presents levels ofFactor V in OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1. FIG. 6Bpresents levels of Factor VIII in OCR-LRWB/CPDA1 and conventionallystored LRWB/CPDA1. FIG. 6C presents Protein C activity in OCR-LRWB/CPDA1and conventionally stored LRWB/CPDA1. FIG. 6D presents Protein Sactivity in OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1. FIG. 6Epresents levels of von Willebrand Factor (vWF) in OCR-LRWB/CPDA1 andconventionally stored LRWB/CPDA1. In graphs presenting plasma clottingfactors, dashed lines=ORC-LRWB/CPDA1 stored blood, and solidlines=conventionally stored blood.

FIGS. 7A to 7D are graphs presenting the results of experimentsaccording to the present disclosure comparing the storage ofleukoreduced whole blood collected in anticoagulant solution CPDA1(LRWB/CPDA1) under oxygen and carbon dioxide reduced (OCR) andconventionally stored LRWB/CPDA1 over a period of 21 days. FIG. 7Apresents the speed at which fibrin build up and crosslinking takes place(TEG Angle) in OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1. FIG.7B presents a comparison of blood kinetics (TEG K) in OCR-LRWB/CPDA1 andconventionally stored LRWB/CPDA1. FIG. 7C presents the maximum amplitudein OCR-LRWB/CPDA1 and conventionally stored LRWB/CPDA1. FIG. 7D presentsthe reaction time in OCR-LRWB/CPDA1 and conventionally storedLRWB/CPDA1. In graphs presenting thromboelastography (TEG) parameters,dashed lines=ORC-LRWB/CPDA1 stored blood, and solid lines=conventionallystored blood.

DETAILED DESCRIPTION

Unless defined otherwise, technical and scientific terms as used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art. One skilled in the art will recognize many methods can be usedin the practice of the present disclosure. Indeed, the presentdisclosure is in no way limited to the methods and materials described.Any references cited herein are incorporated by reference in theirentireties. For purposes of the present disclosure, the following termsare defined below.

As used herein, the term “patient” includes a person in need of amedical procedure receiving a blood product.

As used herein, the term “multiple transfusion” includes a patientreceiving more than 195 units of blood. In another aspect, a multipletransfusion can include a patient receiving at least 1×10⁵ mL of blood.In another aspect, multiple transfusion includes a patient receivingfrom 1 to 1×10⁵ mL of blood. In another aspect, multiple transfusionincludes a patient receiving from 1×10⁴ to 1×10⁵ mL of blood.

As used herein, the term “blood” refers to whole blood, leukoreducedRBCs, platelet reduced RBCs, and leukocyte and platelet reduced RBCs.The term blood further includes packed red blood cells, platelet reducedpacked red blood cells, leukocyte reduced packed red blood cells(LRpRBC), and leukocyte and platelet reduced packed red blood cells. Thetemperature of blood can vary depending on the stage of the collectionprocess, starting at the normal body temperature of 37° C. at the timeand point of collection, but decreasing rapidly to about 30° C. as soonas the blood leaves the patient's body and further thereafter to roomtemperature in about 6 hours when untreated, and ultimately beingrefrigerated at between about 4° C. and 6° C.

As used herein, “blood product” includes separated platelets, plasma, orwhite blood cells.

As used herein, “recovered blood product” includes separated platelets,plasma, or white blood cells collected from a donor.

As used herein, “recovered blood” includes whole blood and red bloodcells collected from a donor and previously stored under oxygen reducedconditions. In one aspect of the present disclosure, suitable blood foruse in this method includes oxygen reduced leukoreduced packed red bloodcells (OR-LRpRBC), oxygen reduced leukoreduced packed red blood cellswith platelets (OR-LRpRBC+PLT), oxygen and carbon dioxide reducedleukoreduced packed red blood cells (OCR-LRpRBC), or oxygen and carbondioxide reduced leukoreduced packed red blood cells with platelets(OCR-LRpRBC+PLT) obtained from oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), oxygen and carbon dioxide reduced leukoreduced wholeblood with platelets (OCR-LRWB+PLT) after at least one week of storage.In another aspect, the suitable blood for use in this method is storedfor up to 42 days. In another aspect, the suitable blood for use in thismethod is stored for up to 56 days. In another aspect, the suitableblood for use in this method is stored for up to 64 days.

As used herein, a method of obtaining “component separated bloodproducts” includes obtaining recycled blood from a blood bank inventoryand separating into platelets, plasma, and white blood cells. Suitableblood for use in this method comprises oxygen reduced whole blood havingan anticoagulant and oxygen reduced leukoreduced whole blood having ananticoagulant. In an aspect of the present disclosure, a componentseparated oxygen reduced blood is stored for up to six weeks. In anotheraspect, a component separated oxygen reduced blood includes an additivesolution. In certain aspects, the additive solution may be AS-1. Incertain aspects, the additive solution is AS-3 (Nutricel®). In certainaspects, the additive solution is AS-5. In certain aspects, the additivesolution is SAGM. In certain aspects, the additive solution is PAGG-SM.In certain aspects, the additive solution is PAGG-GM. In certainaspects, the additive solution is MAP. In certain aspects, the additivesolution is SOLX. In certain aspects, the additive solution is ESOL. Incertain aspects, the additive solution is EAS61. In certain aspects, theadditive solution is OFAS1. In certain aspects, the additive solution isOFAS3. In certain aspects, the additive solution is a combination ofAS-1, AS-3 (Nutricel®), AS-5, SAGM, PAGG-SM, PAGG-GM, MAP, SOLX, ESOL,EAS61, OFAS1, and OFAS3, alone or in combination.

As used herein, “reconstituted WB” includes providing platelets, RBC,and plasma in parallel to a patient during transfusion.

As used herein, “derived WB” includes oxygen reduced and oxygen andcarbon dioxide reduced whole blood.

As used herein, “stored red blood cells” includes oxygen reduced oroxygen and carbon dioxide reduced red blood cells stored from 1 to 6° C.In an aspect, stored red blood cells include red blood cells (RBC)present in whole blood. In another aspect, stored red blood cellsinclude RBC present in leukoreduced whole blood. In another aspect,stored red blood cells include red blood cells (RBC) present inleukoreduced RBC. In a further aspect, stored red blood cells includered blood cells (RBC) present in platelet reduced RBC. In yet anotheraspect, stored red blood cells include red blood cells (RBC) present inleukoreduced and platelet reduced RBC.

As used herein, “whole blood” includes white blood cells (WBCs),platelets suspended in plasma, and includes electrolytes, hormones,vitamins, antibodies, etc. In whole blood, white blood cells arenormally present in the range of between 4.5 and 11.0×10⁹ cells/L, andthe normal RBC range at sea level is 4.6-6.2×10¹²/L for men and4.2-5.4×10¹²/L for women. The normal hematocrit, or percent packed cellvolume, is about 40-54% for men and about 38-47% for women. The plateletcount is normally 150-450×10⁹/L for both men and women. Whole blood iscollected from a blood donor, and is usually combined with ananticoagulant. Whole blood, when collected is initially at about 37° C.and rapidly cools to about 30° C. during and shortly after collection,but slowly cools to ambient temperature over about 6 hours. Whole bloodmay be processed according to methods of the present disclosure atcollection, beginning at 30-37° C., or at room temperature (typicallyabout 25° C.). As used herein, a “unit” of blood is about 450-500 mlincluding anticoagulant. Suitable anticoagulants include CPD, CPDA1,ACD, and ACD-A. As used herein, “time collected” (Tc) is the time atwhich blood is collected from the patient.

As used herein, “red blood cells” (RBCs), stored red blood cells, oxygenreduced red blood cells, and oxygen and carbon dioxide reduced red bloodcells, include RBCs present in whole blood, leukoreduced RBCs, plateletreduced RBCs, leukocyte and platelet reduced RBCs, and packed red bloodcells (pRBCs). Human red blood cells in vivo are in a dynamic state. Thered blood cells contain hemoglobin, the iron-containing protein thatcarries oxygen throughout the body and gives red blood its color. Thepercentage of blood volume composed of red blood cells is called thehematocrit. As used herein, unless otherwise limited, RBCs also includespacked red blood cells (pRBCs). Packed red blood cells are prepared fromwhole blood using centrifugation techniques commonly known in the art.As used herein, unless otherwise indicated, the hematocrit of pRBCs isabout 70%. As used herein, oxygen reduced RBC (OR-RBC) can includeoxygen and carbon dioxide (OCR-) reduced RBC (OCR-RBC)

As used herein, “leukoreduced whole blood” (LRWB) includes whole bloodhaving an anticoagulant that has been treated to remove white bloodcells and platelets, usually by filtration or centrifugation.Leukoreduced whole blood has levels of white blood cells that arereduced by at least 5 logs.

As used herein, “oxygen reduced leukoreduced whole blood” (OR-LRWB) caninclude oxygen and carbon dioxide reduced leukoreduced whole blood(OCR-LRWB).

As used herein, “leukoreduced whole blood with platelets” (LRWB+PLT)includes oxygen reduced (OR-) whole blood having an anticoagulant andleukoreduced with a platelet-sparing filter. As used herein, oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT) caninclude oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT).

As used herein, “leukoreduced packed red blood cells” (LRpRBC) includespacked red blood cells having oxygen reduced (OR-) whole blood having ananticoagulant that has been treated to remove white blood cells, usuallyby filtration or centrifugation. As used herein, oxygen reducedleukoreduced packed red blood cells (OR-LRpRBC) can include oxygen andcarbon dioxide reduced leukoreduced packed red blood cells (OCR-LRpRBC).

As used herein, “leukoreduced packed red blood cells with platelets”(LRpRBC+PLT) includes packed red blood cells having platelets obtainedfrom oxygen reduced whole blood having an anticoagulant that has beentreated to remove white blood cells with a platelet-sparing filter. Asused herein, oxygen reduced leukoreduced packed red blood cells withplatelets (OR-LRpRBC+PLT) can include oxygen and carbon dioxide reducedleukoreduced packed red blood cells with platelets (OCR-LRpRBC+PLT).

In aspects of the present disclosure, the method and compositions mayinclude adding an additive solution to the packed RBCs to form asuspension. A number of additive solutions are known in the art. Incertain aspects, the additive solution may be selected from the groupconsisting of AS-1, AS-3 (Nutricel®), AS-5, SAGM, PAGG-SM, PAGG-GM, MAP,AS-7, ESOL-5, EAS61, OFAS1, and OFAS3, alone or in combination. AdditiveAS-1 is disclosed in Heaton et al., “Use of Adsol preservation solutionfor prolonged storage of low viscosity AS-1 red blood cells,” Br JHaematol., 57(3):467-78 (1984). In a further aspect, the additivesolution may have a pH of from 5.0 to 9.0. In another aspect, theadditive may include an antioxidant. In some aspects according thepresent disclosure, the antioxidant may be quercetin, alpha-tocopherol,ascorbic acid, or enzyme inhibitors for oxidases.

As used herein the term “about” refers to ±10%.

The terms “comprises,” “comprising,” “includes,” “including,” “having,”and their conjugates mean “including but not limited to.”

The term “consisting of” means “including and limited to.”

The term “consisting essentially of” means that the composition, methodor structure may include additional ingredients, steps and/or parts, butonly if the additional ingredients, steps and/or parts do not materiallyalter the basic and novel characteristics of the claimed composition,method or structure.

As used herein, the singular forms “a,” “an,” and “the” include pluralreferences unless the context clearly dictates otherwise. For example,the term “a compound” or “at least one compound” may include a pluralityof compounds, including mixtures thereof.

Throughout this application, various aspects of this disclosure may bepresented in a range format. It should be understood that thedescription in range format is merely for convenience and brevity andshould not be construed as an inflexible limitation on the scope of thedisclosure. Accordingly, the description of a range should be consideredto have specifically disclosed all the possible subranges as well asindividual numerical values within that range. For example, descriptionof a range such as “from 1 to 6” should be considered to havespecifically disclosed subranges such as “from 1 to 3,” “from 1 to 4,”“from 1 to 5,” “from 2 to 4,” “from 2 to 6,” “from 3 to 6,” etc., aswell as individual numbers within that range, for example, 1, 2, 3, 4,5, and 6. This applies regardless of the breadth of the range.

Whenever a numerical range is indicated herein, it is meant to includeany cited numeral (fractional or integral) within the indicated range.The phrases “ranging/ranges between” a first indicate number and asecond indicate number and “ranging/ranges from” a first indicate number“to” a second indicate number are used herein interchangeably and aremeant to include the first and second indicated numbers and all thefractional and integral numerals therebetween.

As used herein the term “method” refers to manners, means, techniques,and procedures for accomplishing a given task including, but not limitedto, those manners, means, techniques, and procedures either known to orreadily developed from known manners, means, techniques, and proceduresby practitioners of the chemical, pharmacological, biological,biochemical, and medical arts.

As used herein, the term “equivalent” means that the measured values ofoxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT), when compared the measured values of otherwiseequivalently treated conventionally stored blood, are within 1 standarddeviation of each other with a sample size of at least 5 for eachcompared measured condition.

As used herein, the term “greater” or “increased” means that themeasured values of oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT), when compared OR-WB, when compared to themeasured values of otherwise equivalently treated conventionally storedblood, are at least 1 standard deviation greater, with a sample size ofat least 5 for each compared measured condition.

As used herein, the term “decreased” or “less” means that the measuredvalues of oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT), when compared OR-WB, when compared to themeasured values of otherwise equivalently treated conventionally storedblood, are at least 1 standard deviation lower, with a sample size of atleast 5 for each compared measured condition.

As used herein, the terms “conventionally stored,” “conventionalstorage,” and “conventional conditions” include whole blood,leukoreduced RBCs, platelet reduced RBCs, leukocyte and platelet reducedRBCs, packed red blood cells, platelet reduced packed red blood cells,leukocyte reduced packed red blood cells (LRpRBC), and leukocyte andplatelet reduced packed red blood cells stored in oxygen and carbondioxide permeable container at 1 to 6° C. without gas reduction stepsprior to storage. In an aspect of the present disclosure, both oxygenand carbon dioxide increase to ambient levels over time inconventionally stored whole blood, leukoreduced RBCs, platelet reducedRBCs, leukocyte and platelet reduced RBCs, packed red blood cells,platelet reduced packed red blood cells, leukocyte reduced packed redblood cells (LRpRBC), and leukocyte and platelet reduced packed redblood cells, due to oxygen and carbon dioxide container permeability.While not traditionally considered conventional, for the purposes of thepresent disclosure, conventional storage can include storage attemperatures above 6° C. Also, while not traditionally consideredconventional, for the purposes of the present disclosure, conventionalstorage can include storage at freezing temperatures.

The present disclosure provides for, and includes, methods to providedesirable characteristics to blood products for transfusion. It has beendiscovered that depletion of oxygen from packed red blood cells resultsin reduced accumulations of unbound cytokine, particularly RANTES (C—Cmotif chemokine ligand 5, CCL5) and eotaxin (C—C motif chemokine ligand11, CCL11), as well as cell-free hemoglobin, and 8-isoprostane F₂a. Notto be limited by theory, it is thought that RANTES and eotaxin arenormally sequestered by binding to the DARC (atypical chemokine receptor1, ACKR1) and oxidative stress damages DARC and releases the boundchemokines. Thus, while overall content of the chemokines does notchange, the effective concentration (e.g., freely diffusible andunbound) increases and is then available to affect a transfused patient.As will be understood, the presence of these active chemokines (actingin a dose dependent manner) can be detrimental to trauma and otherpatients receiving two or more transfusions. These findings demonstratean unexpected benefit of anaerobically stored blood, in addition to thedesirable efficient oxygen delivery associated with elevated 2,3-DPGvalues, and provides a potential reduction in some of the components ofthe storage lesion resultant from pRBC oxidative damage during storage.These cytokines are known to be negatively associated with patientoutcome in some patient populations. Accordingly, the discovery thatunbound cytokine accumulation can be reduced provides for improvedmethods of treating patients susceptible to cytokines.

The present disclosure provides for, and includes, improving thesurvival of a patient in need of multiple transfusions by providingstored red blood cells that have been oxygen reduced (OR-stored RBCs) toa patient in need thereof receiving a medical procedure. Not to belimited by theory, it is believed that increased levels of cytokineshave adverse effects on recipient patients that increases morbidity. Inan aspect, the stored red blood cells are oxygen reduced (OR). In afurther aspect, the stored red blood cells are both oxygen and carbondioxide reduced (OCR). As shown in the examples, in OCR samples, thelevels of ATP are decreased and maintained at lower levels for at least15 days, while in OR samples, the levels of ATP are increased comparedto conventionally stored samples (see FIG. 4A). As shown in theexamples, in OCR samples, the levels of 2,3-DPG are increased andmaintained at high levels for at least 15 days, while in OR samples,2,3-DPG levels are increased over conventional storing but not as highas 2,3-DPG levels of OCR samples (see FIG. 4B). Further, as shown in theexamples, hemolysis is equivalent in OR, OCR, and conventionally storedsamples.

In an aspect of the present disclosure, cytokines comprise monocytechemotactic protein-1 (MCP-1). In another aspect, cytokines compriseregulated on activation normal T cell expressed and secreted (RANTES).In another aspect, cytokines comprise angiogenin. In another aspect ofthe present disclosure, cytokines comprise tumor necrosis factor-alpha(TNF-α). In another aspect, cytokines comprise epidermal growth factor(EGF). In a further aspect, cytokines comprise platelet-derived growthfactor (PDGF).

In an aspect of the present disclosure, the level of the factor RANTESis less than 500 pg/ml after 21 days under OR conditions. In anotheraspect, the level of the factor RANTES is less than 400 pg/ml after 21days under OR conditions. In another aspect, the level of the factorRANTES is less than 300 pg/ml after 21 days under OR conditions. Inanother aspect, the level of the factor RANTES is more than 100 pg/mlafter 21 days under OR conditions. In a further aspect, the level of thefactor RANTES is from 0 to 300 pg/ml after 21 days under OR conditions.

In an aspect of the present disclosure, the level of the factor eotaxinis less than 150 pg/ml after 21 days under OR conditions. In anotheraspect, the level of the factor eotaxin is less than 100 pg/ml after 21days under OR conditions. In another aspect, the level of the factoreotaxin is from 0 to 100 pg/ml after 21 days under OR conditions. Inanother aspect, the level of the factor eotaxin is preferably 100 pg/mlafter 21 days under OR conditions. In another aspect, the level of thefactor eotaxin is more than 100 pg/ml after 21 days under OR conditions.In a further aspect, the level of the factor eotaxin is from 0 to 300pg/ml after 21 days under OR conditions.

In aspects according to the present disclosure, the OR-stored RBCs areselected from the group consisting of oxygen reduced leukoreduced wholeblood (OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen reduced leukoreduced packed red blood cells(OR-LRpRBC), oxygen reduced leukoreduced packed red blood cells withplatelets (OR-LRpRBC+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), oxygen and carbon dioxide reducedleukoreduced whole blood with platelets (OCR-LRWB+PLT), oxygen andcarbon dioxide reduced leukoreduced packed red blood cells (OCR-LRpRBC),oxygen and carbon dioxide reduced leukoreduced packed red blood cellswith platelets (OCR-LRpRBC+PLT), and combinations thereof. In otheraspects, wherein said OR-stored RBCs comprise oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT).

In an aspect, a patient in need of multiple transfusions is a traumapatient. In another aspect, a patient in need of multiple transfusionsis a transplant patient. In another aspect, a patient in need ofmultiple transfusions is a cardiac surgery patient. In another aspect, apatient in need of multiple transfusions is an obstetrics patient. Inanother aspect, a patient in need of multiple transfusions is agastrointestinal (GI) surgery patient. In a further aspect, a patient isan orthopedic surgery patient.

In an aspect, a patient in need of multiple transfusions is a traumapatient. In another aspect, a patient in need of multiple transfusionsis a hemorrhagic trauma patient. In a further aspect, a patient in needof multiple transfusions is a blunt trauma patient.

In an aspect, the reduction of cytokines in oxygen reduced stored packedred blood cells provides for improved treatment of cancer patients inneed of blood transfusions. It is known in the art that cytokines areassociated with negative patient outcome for patients receivingperioperative blood transfusions for surgical treatments of cancerpatients. In an aspect, the oxygen depleted, cytokine reduced bloodproducts are provided to a cancer patient prior to undergoing surgery.In another aspect, the oxygen depleted, cytokine reduced blood productsare provided to a cancer patient during surgery. In another aspect, theoxygen depleted, cytokine reduced blood products are provided to acancer patient following surgery.

In aspects according to the present disclosure, the oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) hashigher levels of 2,3-DPG compared to conventionally stored leukoreducedwhole blood (WB) and provides for improved oxygen delivery. Underanaerobic conditions, 2,3-DPG levels can be maintained in whole bloodfor up to 4 weeks. In an aspect, the 2,3-DPG levels are maintained above50% of physiologic levels for up to four weeks. In aspects according tothe present disclosure, improved 2,3-DPG levels are maintained for at 2weeks. In other aspects, 2,3-DPG levels are maintained for three weeks.In an aspect, the 2,3-DPG level of the oxygen reduced leukoreduced wholeblood (OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is at least 80% or higher thanthe 2,3-DPG level of the blood at day zero. In another aspect, the2,3-DPG level of the oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) is at least 5 to 20 DPG μmol/gHb.

Also provided for and included in the present disclosure is oxygenreduced leukoreduced whole blood (OR-LRWB), oxygen reduced leukoreducedwhole blood with platelets (OR-LRWB+PLT), oxygen and carbon dioxidereduced leukoreduced whole blood (OCR-LRWB), or oxygen and carbondioxide reduced leukoreduced whole blood with platelets (OCR-LRWB+PLT)that have depleted whole blood (OR-WB) that has reduced levels ofbiological response modifiers (BRMs) relative to conventionally storedwhole blood. In certain aspects, the BRM present in oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) is abouthalf the level of conventionally stored blood after 21 days. In anaspect, the oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has levels of cytokines that are relativelyunchanged after 10 days in storage under anaerobic conditions. Inanother aspect, the cytokine level is relatively unchanged after 30 daysof storage. In another aspect, the cytokine level is relativelyunchanged after 40 days of storage. As used herein, “relativelyunchanged” means that the concentration of cytokine, normalized tohemoglobin levels is within 1 standard deviation of the initialnormalized concentration of cytokine.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels of thecytokine eotaxin compared to conventionally stored whole blood. In anaspect, the level of eotaxin in oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is about half the level ofeotaxin present in conventionally stored blood after 21 days, normalizedto the hemoglobin concentration. In an aspect, the level of eotaxin inoxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) is about 25% or less of the level of eotaxin present inconventionally stored blood after 40 days.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels of thecytokine RANTES (regulated on activation, normal T cell expressed andsecreted) compared to conventionally stored whole blood. In an aspect,the level of RANTES in oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is about half the level ofRANTES present in conventionally stored blood after 21 days, normalizedto the hemoglobin concentration. In an aspect, the level of RANTES inoxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) is about 25% or less of the level of RANTES present inconventionally stored blood after 40 days.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels of monocytechemotactic protein-1 (MCP-1) compared to conventionally stored wholeblood. In an aspect, the level of MCP-1 in oxygen reduced leukoreducedwhole blood (OR-LRWB), oxygen reduced leukoreduced whole blood withplatelets (OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreducedwhole blood (OCR-LRWB), or oxygen and carbon dioxide reducedleukoreduced whole blood with platelets (OCR-LRWB+PLT) is about half thelevel of MCP-1 present in conventionally stored blood after 21 days,normalized to the hemoglobin concentration. In an aspect, the level ofMCP-1 in oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) is about 25% or less of the level of MCP-1present in conventionally stored blood after 40 days.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels ofangiogenin compared to conventionally stored whole blood. In an aspect,the level of angiogenin in oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is about half the level ofangiogenin present in conventionally stored blood after 21 days,normalized to the hemoglobin concentration. In an aspect, the level ofangiogenin in oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) is about 25% or less of the level of angiogeninpresent in conventionally stored blood after 40 days.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels of tumornecrosis factor-alpha (TNF-α) compared to conventionally stored wholeblood. In an aspect, the level of TNF-α in oxygen reduced leukoreducedwhole blood (OR-LRWB), oxygen reduced leukoreduced whole blood withplatelets (OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreducedwhole blood (OCR-LRWB), or oxygen and carbon dioxide reducedleukoreduced whole blood with platelets (OCR-LRWB+PLT) is about half thelevel of TNF-α present in conventionally stored blood after 21 days,normalized to the hemoglobin concentration. In an aspect, the level ofTNF-α in oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) is about 25% or less of the level of TNF-αpresent in conventionally stored blood after 40 days.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels ofepidermal growth factor (EGF) compared to conventionally stored wholeblood. In an aspect, the level of EGF in oxygen reduced leukoreducedwhole blood (OR-LRWB), oxygen reduced leukoreduced whole blood withplatelets (OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreducedwhole blood (OCR-LRWB), or oxygen and carbon dioxide reducedleukoreduced whole blood with platelets (OCR-LRWB+PLT) is about half thelevel of EGF present in conventionally stored blood after 21 days,normalized to the hemoglobin concentration. In an aspect, the level ofEGF in oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) is about 25% or less of the level of EGF present inconventionally stored blood after 40 days.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels of solubleCD40 ligand (sCD40L) compared to conventionally stored whole blood. Inan aspect, the level of sCD40L in oxygen reduced leukoreduced wholeblood (OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is about half the level ofsCD40L present in conventionally stored blood after 21 days, normalizedto the hemoglobin concentration. In an aspect, the level of sCD40L inoxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) is about 25% or less of the level of sCD40L present inconventionally stored blood after 40 days.

In certain aspects, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has reduced levels ofplatelet-derived growth factor (PDGF) compared to conventionally storedwhole blood. In an aspect, the level of PDGF in oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) is abouthalf the level of PDGF present in conventionally stored blood after 21days, normalized to the hemoglobin concentration. In an aspect, thelevel of PDGF in oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) is about 25% or less of the level of PDGFpresent in conventionally stored blood after 40 days.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) thatprovides a reduced inflammatory response when transfused into a patientcompared to conventionally stored oxygen reduced leukoreduced wholeblood (OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT).

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB) that provides blood products havinghigher RBC deformability compared to conventionally stored bloodproducts. In certain aspects, the blood product is a whole bloodproduct. In another aspect, the blood product is leukoreduced wholeblood. In another aspect, the blood product is leukoreduced and plateletreduced whole blood. In a further aspect, the blood product isleukoreduced packed red blood cells or leuko- and platelet-reducedpacked red blood cells.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB) that has coagulation parameters thatare at least 75% of the coagulation parameter of conventionally storedwhole blood as measured by thromboelastography (TEG). In an aspect, theTEG coagulation parameter of the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is equivalent toconventionally stored blood. In yet another aspect, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) has a TEGcoagulation parameter that is greater than the TEG coagulation parameterof conventionally stored blood. In an aspect, the TEG Angle is more than40°. In another aspect, the TEG kinetics (K) is less than 5 mins. Inanother aspect the TEG K is between 1 to 5 mins. In another aspect, theTEG maximum amplitude (TEG MA) is more than 50 mm. In another aspect,the TEG maximum amplitude (TEG MA) is less than 70 mm. In anotheraspect, the TEG maximum amplitude (TEG MA) is between 30 to 65 mm. Inanother aspect, the TEG reaction time (TEG R) is less than 10 mins. Inanother aspect, the TEG reaction time (TEG R) is less than 8 mins. Inanother aspect, the TEG reaction time (TEG R) is at least 3 mins. In afurther aspect, the TEG reaction time (TEG R) is between 4 to 8 mins.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB) that has coagulation parameters thatare at least 75% of the coagulation parameter of conventionally storedwhole blood as measured by prothrombin time (PT). In an aspect, the PTof the oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) is equivalent to conventionally stored blood. In yetanother aspect, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has a PT that is greater than the PT ofconventionally stored blood. In a further aspect, oxygen reducedleukoreduced whole blood (OR-LRWB) has a PT of less than 15 seconds. Inanother aspect, oxygen reduced leukoreduced whole blood (OR-LRWB) has aPT of more than 5 seconds. In another aspect, oxygen reducedleukoreduced whole blood (OR-LRWB) or has a PT of 10 to 15 seconds.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that hascoagulation parameters that are at least 75% of the coagulationparameter of conventionally stored whole blood as measured by partialthromboplastin time (PTT). In an aspect, the PTT of the oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) isequivalent to conventionally stored blood. In yet another aspect, oxygenreduced leukoreduced whole blood (OR-LRWB), oxygen reduced leukoreducedwhole blood with platelets (OR-LRWB+PLT), oxygen and carbon dioxidereduced leukoreduced whole blood (OCR-LRWB), or oxygen and carbondioxide reduced leukoreduced whole blood with platelets (OCR-LRWB+PLT)has a PTT that is greater than the PTT of conventionally stored blood.In a further aspect, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has a PTT that is greater than 25 seconds. Inanother aspect, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has a PTT that is less than 40 seconds. Inanother aspect, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has a PTT that is between 32 to 42 seconds.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that havewhole blood (OR-WB) that has coagulation parameters that are at least75% of the coagulation parameter of conventionally stored whole blood asmeasured by the level of fibrinogen activity. In an aspect, thefibrinogen activity of the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is equivalent toconventionally stored blood. In yet another aspect, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) has afibrinogen activity that is greater than the fibrinogen activity ofconventionally stored blood. In a further aspect, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) has afibrinogen level that is at least 200 mg/ml. In another aspect, oxygenreduced leukoreduced whole blood (OR-LRWB), oxygen reduced leukoreducedwhole blood with platelets (OR-LRWB+PLT), oxygen and carbon dioxidereduced leukoreduced whole blood (OCR-LRWB), or oxygen and carbondioxide reduced leukoreduced whole blood with platelets (OCR-LRWB+PLT)has a fibrinogen level that is at most 400 mg/ml. In another aspect,oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) has a fibrinogen level that is from 250 to 350 mg/ml. Inanother aspect, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has a fibrinogen level that is from 250 to 300mg/ml.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that havewhole blood (OR-WB) that has coagulation parameters that are at least75% of the coagulation parameter of conventionally stored whole blood asmeasured by D-dimer analysis. In an aspect, the D-dimer value of theoxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) is equivalent to conventionally stored blood. In yetanother aspect, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has a D-dimer value that is greater than theD-dimer value of conventionally stored blood.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that havewhole blood (OR-WB) that has coagulation parameters that are at least75% of the coagulation parameter of conventionally stored whole blood asmeasured by a thrombin generation assay. In an aspect, the thrombingeneration value of the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) is equivalent toconventionally stored blood. In yet another aspect, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) has athrombin generation value that is greater than the thrombin generationvalue of conventionally stored blood.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that hasplatelet function parameters that are at least 75% of the plateletfunction parameters of conventionally stored whole blood as measured bya platelet aggregometer. In an aspect, the platelet function parametersof the oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) are equivalent to conventionally stored blood. In yetanother aspect, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has platelet function parameters that aregreater than the platelet function parameters of conventionally storedblood.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that haslevels of clotting factor that are at least 75% of the levels ofclotting factor in conventionally stored blood. In an aspect, the levelof clotting factors is equivalent to that of conventionally storedblood. In yet other aspects, oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has a platelet functionparameter that is greater than the platelet function parameter ofconventionally stored blood. Not to be limited by theory, it is thoughtthat oxidative degradation of clotting factors is prevented or reducedin oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) and provides for higher levels of clotting factoractivity. Methods to evaluate the effect of treatments on coagulabilityare known in the art, for example as described by Pidcoke et al.,“Primary hemostatic capacity of whole blood: a comprehensive analysis ofpathogen reduction and refrigeration effects over time,” Transfusion53:137S-149S (2013).

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that hasa level of Factor V that has a specific activity that is at least 75% ofthe level of Factor V activity present in conventionally stored blood.In an aspect, the specific activity of Factor V is equivalent to that ofconventionally stored blood. In yet other aspects, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) has aspecific activity of Factor V that is greater than the platelet functionparameter of conventionally stored blood. Methods of measuring thespecific activity of Factor V are known in the art.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that hasa level of Factor V that has a specific activity that is at least 75% ofthe level of Factor VIII activity present in conventionally storedblood. In an aspect, the specific activity of Factor VIII is equivalentto that of conventionally stored blood. In yet other aspects, oxygenreduced leukoreduced whole blood (OR-LRWB), oxygen reduced leukoreducedwhole blood with platelets (OR-LRWB+PLT), oxygen and carbon dioxidereduced leukoreduced whole blood (OCR-LRWB), or oxygen and carbondioxide reduced leukoreduced whole blood with platelets (OCR-LRWB+PLT)has a specific activity of Factor VIII that is greater than the plateletfunction parameter of conventionally stored blood. Methods of measuringthe specific activity of Factor VIII are known in the art. In oneaspect, oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has a specific activity of Factor V that isless than 40% after 21 days of storage.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that hasa level of antithrombin (AT) that has a specific activity that is atleast 75% of the level of AT activity present in conventionally storedblood. In an aspect, the specific activity of AT is equivalent to thatof conventionally stored blood. In yet other aspects, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) has aspecific activity of AT that is greater than the platelet functionparameter of conventionally stored blood. Methods of measuring thespecific activity of AT are known in the art.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that hasa level of Factor XIV (autoprothrombin IIA or Protein C) that has aspecific activity that is at least 75% of the level of Factor XIVactivity present in conventionally stored blood. In an aspect, thespecific activity of Factor XIV is equivalent to that of conventionallystored blood. In yet other aspects, oxygen reduced leukoreduced wholeblood (OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) has a specific activity ofFactor XIV that is greater than the platelet function parameter ofconventionally stored blood. Methods of measuring the specific activityof Factor XIV are known in the art.

The present disclosure provides for, and includes, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) that hasa level of Von Willebrand factor (vWF) that has a specific activity thatis at least 75% of the level of vWF activity present in conventionallystored blood. In an aspect, the specific activity of vWF is equivalentto that of conventionally stored blood. In yet other aspects, oxygenreduced leukoreduced whole blood (OR-LRWB), oxygen reduced leukoreducedwhole blood with platelets (OR-LRWB+PLT), oxygen and carbon dioxidereduced leukoreduced whole blood (OCR-LRWB), or oxygen and carbondioxide reduced leukoreduced whole blood with platelets (OCR-LRWB+PLT)has a specific activity of vWF that is greater than the plateletfunction parameter of conventionally stored blood. In another aspect,oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) has a specific activity of vWF that is less than theplatelet function parameter of conventionally stored blood. Methods ofmeasuring the specific activity of vWF are known in the art.

The present disclosure provides for, and includes, methods to extend thestored shelf life of whole blood from the current 2 weeks to 3 weeks andbeyond. The oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) of the present disclosure provides for patientoutcomes at three weeks that are equivalent to patient outcome providedby whole blood that has been stored for two weeks under conventionalconditions.

As provided herein, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has decreased side effects for transfusionrecipients as compared to conventionally stored blood. In an aspect,oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) has a decreased inflammatory response after two weeksstorage as compared to conventionally stored blood. In other aspects,the inflammatory response is reduced relative to conventionally storedblood after three weeks. In an aspect, the oxygen reduced leukoreducedwhole blood (OR-LRWB), oxygen reduced leukoreduced whole blood withplatelets (OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreducedwhole blood (OCR-LRWB), or oxygen and carbon dioxide reducedleukoreduced whole blood with platelets (OCR-LRWB+PLT) can be stored formore than three weeks and retain the levels of inflammatory response ascompared to conventionally stored blood after two weeks.

As provided herein, oxygen reduced leukoreduced whole blood (OR-LRWB),oxygen reduced leukoreduced whole blood with platelets (OR-LRWB+PLT),oxygen and carbon dioxide reduced leukoreduced whole blood (OCR-LRWB),or oxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) has decreased side effects for transfusionrecipients as compared to conventionally stored blood. In an aspect,oxygen reduced leukoreduced whole blood (OR-LRWB), oxygen reducedleukoreduced whole blood with platelets (OR-LRWB+PLT), oxygen and carbondioxide reduced leukoreduced whole blood (OCR-LRWB), or oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT) has a decreased immune modulation after two weeks storageas compared to conventionally stored blood. In other aspects, the immunemodulation is reduced relative to conventionally stored blood afterthree weeks. In an aspect, the oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) can be stored for more thanthree weeks and retain the levels of immune modulation as compared toconventionally stored blood after two weeks.

The methods and whole blood products of the present disclosure provideimproved patient outcomes when transfused. In particular, oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) providesfor improved survival in cancer patients when provided in perioperativetransfusions. In a certain aspect, the oxygen reduced leukoreduced wholeblood (OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT) provides for reduced mortalityand improved survival when provided perioperatively to pancreatic cancerpatients. Not to be limited by theory, the reduced mortality is theresult of the combination of reduced levels of cytokines and improvedoxygen transport and delivery that results from increased levels of2,3-DPG and ATP.

In an aspect, the blood for transfusion to a cancer patient in needthereof has a reduced level of the cytokine regulated on activation,normal T cell expressed and secreted (RANTES). In an aspect, the RANTESlevel is equivalent to the level of RANTES present at the beginning ofstorage. In another aspect, the RANTES level of oxygen reducedleukoreduced whole blood (OR-LRWB), oxygen reduced leukoreduced wholeblood with platelets (OR-LRWB+PLT), oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB), or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT) is lessthan the level of RANTES present in conventionally stored blood. In anaspect, the level of RANTES is less than the level of RANTES present inconventionally stored blood throughout the storage period. In otheraspects, RANTES does not increase during storage.

In an aspect, the blood for transfusion to a cancer patient in needthereof has a reduced level of a CC chemokine that is an eosinophilchemotactic protein, eotaxin. In an aspect, the eotaxin having a reducedlevel in oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) is eotaxin-1, also known as C—C motif chemokine11. In an aspect the eotaxin level is equivalent to the level of eotaxinpresent at the beginning of storage. In another aspect, the eotaxinlevel of oxygen reduced leukoreduced whole blood (OR-LRWB), oxygenreduced leukoreduced whole blood with platelets (OR-LRWB+PLT), oxygenand carbon dioxide reduced leukoreduced whole blood (OCR-LRWB), oroxygen and carbon dioxide reduced leukoreduced whole blood withplatelets (OCR-LRWB+PLT) is less than the level of eotaxin present inconventionally stored blood. In an aspect, the level of eotaxin is lessthan the level of eotaxin present in conventionally stored bloodthroughout the storage period. In other aspects, eotaxin does notincrease during storage.

The methods and whole blood products of the present disclosure providefor reduced multiple organ dysfunction syndrome and improved patientoutcomes when transfused. In particular, oxygen reduced leukoreducedwhole blood (OR-LRWB), oxygen reduced leukoreduced whole blood withplatelets (OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreducedwhole blood (OCR-LRWB), or oxygen and carbon dioxide reducedleukoreduced whole blood with platelets (OCR-LRWB+PLT) provides forreduced multiple organ dysfunction syndrome in trauma patients whenprovided in perioperative transfusions. In a certain aspect, the oxygenreduced leukoreduced whole blood (OR-LRWB), oxygen reduced leukoreducedwhole blood with platelets (OR-LRWB+PLT), oxygen and carbon dioxidereduced leukoreduced whole blood (OCR-LRWB), or oxygen and carbondioxide reduced leukoreduced whole blood with platelets (OCR-LRWB+PLT)provides for reduced multiple organ dysfunction syndrome in traumapatients when provided during emergency treatment.

The present disclosure provides for, and includes, a method of preparingoxygen reduced leukoreduced whole blood comprising obtaining a unit ofwhole blood comprising an anticoagulant, filtering the whole blood toproduce leukoreduced whole blood, depleting the leukoreduced whole bloodof oxygen, and storing the oxygen reduced leukoreduced whole blood underanaerobic conditions.

The present disclosure provides for, and includes, a method of preparingoxygen reduced leukoreduced whole blood that has a pre-storage oxygensaturation of (SO₂) of 30% or less. Whole blood obtained from a donorusing venipuncture has an oxygen saturation ranging from about 30% toabout 70% saturated oxygen (SO₂). In certain aspects, the SO₂ is reducedto 25% or less. In certain aspects, the SO₂ is reduced to 20% or less.In certain aspects, the SO₂ is reduced to 15% or less. In other aspects,the SO₂ is reduced to 10% or less. In yet other aspects, the SO₂ isreduced to 5% or less.

Also provided for and included in the present disclosure arecompositions and methods to prepare compositions of oxygen reduced andcarbon dioxide reduced leukoreduced whole blood. In certain aspects, theSO₂ value is 20% or less and the partial pressure of carbon dioxide isless than 60 mmHg. In other aspects, the partial pressure of carbondioxide is between 10 and 60 mmHg. In another aspect, the partialpressure of carbon dioxide is between 20 and 40 mmHg. Also included arewhole blood compositions and methods that provide for an SO₂ of 15% orless and a partial pressure of carbon dioxide of between 10 and 60 mmHg.In another aspect, the methods and compositions include whole bloodproducts having an SO₂ of 15% or less and a partial pressure of carbondioxide of between 20 and 40 mmHg. In yet another aspect, the bloodcompositions and methods of the present disclosure have an SO₂ of 10% orless and a partial pressure of carbon dioxide of between 10 and 60 mmHg.In other aspects, the blood compositions and methods of the presentdisclosure have an SO₂ of 10% or less and a partial pressure of carbondioxide of between 20 and 40 mmHg. In yet further aspects, the bloodcompositions and methods of the present disclosure have an SO₂ of 5% orless and a partial pressure of carbon dioxide of between 10 and 60 mmHg.In other aspects, the blood compositions and methods of the presentdisclosure have an SO₂ of 5% or less and a partial pressure of carbondioxide of between 20 and 40 mmHg.

Also provided for and included in the present disclosure, arecompositions and methods to prepare compositions of oxygen reduced andcarbon dioxide reduced leukoreduced whole blood. In certain aspects, theSO₂ value is 20% or less and the partial pressure of carbon dioxide isbetween 1 and 60 mmHg. In other aspects, the partial pressure of carbondioxide is between 10 and 60 mmHg. In another aspect, the partialpressure of carbon dioxide is between 20 and 40 mmHg or 1 and 20 mmHg.Also included are whole blood compositions and methods that provide foran SO₂ of 15% or less and a partial pressure of carbon dioxide ofbetween 10 and 60 mmHg. In certain aspects, the SO₂ value is 15% or lessand the partial pressure of carbon dioxide is between 1 and 60 mmHg. Inanother aspect, the methods and compositions include whole bloodproducts having an SO₂ of 15% or less and a partial pressure of carbondioxide of between 20 and 40 mmHg or 1 and 20 mmHg. In yet anotheraspect, the blood compositions and methods of the present disclosurehave an SO₂ of 10% or less and a partial pressure of carbon dioxide ofbetween 1 and 60 mmHg or 10 and 60 mmHg. In other aspects, the bloodcompositions and methods of the present disclosure have an SO₂ of 10% orless and a partial pressure of carbon dioxide of between 20 and 40 mmHgor 1 and 20 mmHg. In yet further aspects, the blood compositions andmethods of the present disclosure have an SO₂ of 5% or less and apartial pressure of carbon dioxide of between 1 and 60 mmHg or 10 and 60mmHg. In other aspects, the blood compositions and methods of thepresent disclosure have an SO₂ of 5% or less and a partial pressure ofcarbon dioxide of between 20 and 40 mmHg or 1 and 20 mmHg.

Notably, and as evidenced in FIGS. 2A, 2B, 3A and 3B, the ATP level instored oxygen reduced blood depends on the partial pressure of CO₂.Specifically, depletion of oxygen to about 10% SO₂ and carbon dioxide toabout 25 mmHg results in increased 2,3-DPG levels that persist beyond 21days, while ATP decreases to a level of about one half of the initialvalue. See FIGS. 2G and 3D. Accordingly, the present disclosure providesfor, and includes the depletion of oxygen to SO₂ levels of about 5% andthe depletion of carbon dioxide to a partial pressure of about 30 to 40mmHg to yield oxygen and carbon dioxide reduced whole blood that hasincreased levels of 2,3-DPG and that retains at least 50% of the initialconcentration of ATP through day 20. In other aspects, the partialpressure of CO₂ can be adjusted to retain ATP levels that are at least75% of the initial ATP value. Adjustment of the level of CO₂ can beexperimentally determined by one of ordinary skill in the art in view ofthe present disclosure.

Prolonged hypothermic storage under conventional conditions is known toimpair deformability of stored RBCs, potentially compromising theirability to perfuse microvascular networks and deliver oxygen to tissuesand vital organs upon transfusion. It is thought that oxidative damagemay be a primary contributor to the loss of RBC biomechanical function;therefore, storing RBCs under oxygen reduced (OR) and oxygen and carbondioxide reduced (OCR) conditions ameliorates oxidative damage, therebypreserving native rheological properties better than conventional(aerobic) storage. For this study, we utilized an in vitro microfluidicsystem that recapitulates an in vivo microvascular capillary bed todemonstrate the effects of reduced oxygen on stored cells.

The present disclosure provides for, and includes, methods for managinga blood bank that improves the availability of blood products for traumavictims and patients that require multiple transfusions and providesconserving the overall blood resources. The component blood products canbe prepared from stored whole blood of the present application and usedfor transfusions or incorporated into massive transfusion kits. Inaddition to the improved blood chemistries (low hemolysis, improved2,3-DPG etc.), the methods provide for improved hemostasis and improveddeformability.

In aspects according the present specification, the method provides formaintaining an inventory of blood units comprising oxygen reduced wholeblood and an anticoagulant as described above, providing one or more ofthe blood units from the inventory for treatment of a patient andrecycling the blood units from the inventory to prepare componentseparated oxygen reduced blood units including oxygen reduced plasma andoxygen reduced leukoreduced packed red blood cells with platelets(OR-LRpRBC+PLT). In aspects, the anticoagulant comprisescitrate-phosphate-dextrose (CPD), citrate-phosphate-dextrose withadenine (CPDA-1), or CP2D.

In an aspect, the specification provides for a method for maintaining aninventory of blood units comprising oxygen and carbon dioxide reducedleukoreduced whole blood and an anticoagulant as described above,providing one or more of the blood units from the inventory fortreatment of a patient and recycling the blood units from the inventoryto prepare component separated oxygen reduced blood units includingoxygen and carbon dioxide reduced plasma and oxygen and carbon dioxidereduced leukoreduced packed red blood cells with platelets(OCR-LRpRBC+PLT). In aspects, the anticoagulant comprisescitrate-phosphate-dextrose (CPD), citrate-phosphate-dextrose withadenine (CPDA-1), or Anticoagulant Citrate Phosphate Double Dextrose(CP2D).

The specification further provides for preparing one or more massivetransfusion kits as described below that include the oxygen reducedplasma, oxygen reduced leukoreduced packed red blood cells withplatelets (OR-LRpRBC+PLT), oxygen and carbon dioxide reduced plasma andoxygen and carbon dioxide reduced leukoreduced packed red blood cellswith platelets (OCR-LRpRBC+PLT).

In aspects according to the invention, the unused blood in the inventoryis recycled after a time period. In certain aspects where theanticoagulant is CPD, the blood units are recycled prior to three weeksof storage. In other aspects where the anticoagulant is CPDA-1, theblood units are recycled prior to five weeks of storage. In yet otheraspects, the blood units are recycled after 2 weeks, or less. In anaspect, blood unit recycling occurs between 2 days and 1 week. Inanother aspect, recycling occurs between 2 days and two weeks. In someaspects, recycling occurs between 1 week and 2 weeks. The timing ofrecycling can be varied consistent with the turnover and needs of theblood facility.

While the recycling process is preferably performed under anaerobicconditions, the process may also be performed under aerobic conditions.Aerobic conditions may provide a cost savings, but may also be indicatedin facilities with higher turnover. In high turnover facilities, therecovered blood components may be used soon after the recycling processand further storage of the blood under anaerobic conditions may providelittle additional benefit.

The method for managing a blood bank further provide for the preparationof a massive transfusion kit as described in detail below.

The present disclosure provides for, and includes, methods to provide asupply of blood products for transfusion medicine comprising depletingoxygen from leukoreduced whole blood to prepare oxygen reducedleukoreduced whole blood (OR-LRWB+PLT), storing the oxygen reducedleukoreduced whole blood (OR-LRWB+PLT) for a time period and providingsaid stored blood to a patient in need thereof. In certain aspects, theleukoreduction step includes platelet reduction to produce oxygenreduced leukoreduced whole blood (OR-LRWB).

The present disclosure provides for, and includes, methods to provide asupply of blood products for transfusion medicine comprising depletingoxygen and carbon dioxide from leukoreduced whole blood to prepareoxygen and carbon dioxide reduced leukoreduced whole blood(OCR-LRWB+PLT), storing the oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB+PLT) for a time period and providingsaid stored blood to a patient in need thereof. In certain aspects, theleukoreduction step includes platelet reduction to produce oxygen andcarbon dioxide reduced leukoreduced whole blood (OCR-LRWB).

The present disclosure provides for, and includes, methods to provide asupply of blood products for transfusion medicine comprising depletingoxygen from leukoreduced whole blood to prepare oxygen reducedleukoreduced whole blood (OR-LRWB+PLT), storing the oxygen reducedleukoreduced whole blood (OR-LRWB+PLT) for a time period and preparingoxygen reduced leukoreduced packed red blood cells with platelets(OR-LRpRBC+PLT). In certain aspects, the leukoreduction step includesplatelet reduction to produce oxygen reduced leukoreduced packed redblood cells (OR-LRpRBC).

The present disclosure provides for, and includes, methods to provide asupply of blood products for transfusion medicine comprising depletingoxygen and carbon dioxide from leukoreduced whole blood to prepareoxygen and carbon dioxide reduced leukoreduced whole blood(OCR-LRWB+PLT), storing the oxygen and carbon dioxide reducedleukoreduced whole blood (OCR-LRWB+PLT) for a time period and preparingoxygen and carbon dioxide reduced leukoreduced packed red blood cellswith platelets (OCR-LRpRBC+PLT). In certain aspects, the leukoreductionstep includes platelet reduction to produce oxygen and carbon dioxidereduced leukoreduced packed red blood cells (OCR-LRpRBC).

As provided herein, the OR-LRpRBC+PLT, OR-LRpRBC, OCR-LRpRBC+PLT, andOCR-LRpRBC may be returned to the store of blood products for supply andstored for a time period until required for use by a patient. In aspectsof the present disclosure, the total time for storage, either as a wholeblood product, or as a packed RBC product may be up to six weeks. Insome aspects, the second storage period is between 2 to 4 weeks.

The methods for providing a supply of blood products include, andprovide, for depleting either oxygen or oxygen and carbon dioxide. Theoxygen levels for the methods to provide a supply of blood products arediscussed in detail above. In certain aspects, the SO₂ value is reducedto 20% or less and the partial pressure of carbon dioxide is less than60 mmHg. In other aspects, the partial pressure of carbon dioxide isbetween 10 and 60 mmHg. In another aspect, the partial pressure ofcarbon dioxide is between 20 and 40 mmHg. Also included are methods thatprovide for an SO₂ of 15% or less and a partial pressure of carbondioxide of between 10 and 60 mmHg. In another aspect, the methodsprovide blood products having an SO₂ of 15% or less and a partialpressure of carbon dioxide of between 20 and 40 mmHg. In yet anotheraspect, the methods of the present disclosure provide blood productshaving an SO₂ of 10% or less and a partial pressure of carbon dioxide ofbetween 10 and 60 mmHg. In other aspects, the methods for providing asupply of blood products provide for an SO₂ of 10% or less and a partialpressure of carbon dioxide of between 20 and 40 mmHg. In yet furtheraspects, the methods provide an SO₂ of 5% or less and a partial pressureof carbon dioxide of between 10 and 60 mmHg. In other aspects, themethods provide an SO₂ of 5% or less and a partial pressure of carbondioxide of between 20 and 40 mmHg.

The present disclosure provides for, and includes, a new bloodcomposition obtained during the blood component recovery process ofOR-LRWB+PLT and OCR-LRWB+PLT. As provided above, while conventionalwhole blood products have an FDA approved shelf life (3 weeks for WB inCPD and 5 weeks in CPDA1), clinicians who use WB limit its shelf lifefrom between 2 and 14 days. In conventional storage, the blood is oftendiscarded. In the present disclosure, the OR-LRWB+PLT and OCR-LRWB+PLTcan be processed using conventional component separation methodsmodified for retaining the blood in the OR or OCR depleted state. Ingeneral, methods are modified to incorporate oxygen and oxygen andcarbon dioxide impermeable barriers to the components and incorporatingfeatures to prevent oxygen ingress. Suitable approaches can be found,for example in International Patent Application No. PCT/US2016/021794,filed Mar. 10, 2016, and International Patent Application No.PCT/US2016/029069, filed Apr. 22, 2016, both of which are herebyincorporated by reference in their entireties.

In aspects according the present disclosure, a blood composition isprovided that comprises oxygen reduced packed red blood cells andplatelets having less than 1×10⁵/L white blood cells. Such compositionsare obtainable from OR-LRWB+PLT and OCR-LRWB+PLT. In an aspect, thelevel of white blood cells is less than 1×10⁴/L white blood cells. Inaspects according to the present disclosure, the oxygen saturation ofthe oxygen reduced leukoreduced packed red blood cells with platelets(OR-LRpRBC+PLT) is less than 30%. In an aspect, the oxygen saturation ofthe oxygen reduced leukoreduced packed red blood cells with platelets(OR-LRpRBC+PLT) is less than 20%. In an aspect, the oxygen saturation ofthe oxygen reduced leukoreduced packed red blood cells with platelets(OR-LRpRBC+PLT) is less than 10%. In a further aspect, the oxygensaturation of the oxygen reduced leukoreduced packed red blood cellswith platelets (OR-LRpRBC+PLT) is less than 5%.

The present disclosure provides for, and includes, oxygen and carbondioxide reduced leukoreduced packed red blood cells with platelets(OCR-LRpRBC+PLT) having less than 30% SO₂ and a storage partial pressureof carbon dioxide of less than 60 mmHg. In an aspect, theOCR-LRpRBC+PLTs have an oxygen saturation of less than 30% and a storagepartial pressure of carbon dioxide between 20 and 40 mmHg. In an aspect,the OCR-LRpRBC+PLTs have an oxygen saturation of less than 30% and astorage partial pressure of carbon dioxide between 0 and 20 mmHg. In anaspect, the OCR-LRpRBC+PLTs have an oxygen saturation of less than 20%and a storage partial pressure of carbon dioxide of less than 60 mmHg.In an aspect, the OCR-LRpRBC+PLTs have an oxygen saturation of less than20% and a storage partial pressure of carbon dioxide between 20 and 40mmHg. In an aspect, the OCR-LRpRBC+PLTs have an oxygen saturation ofless than 20% and a storage partial pressure of carbon dioxide between 0and 20 mmHg. In another aspect, the OCR-LRpRBC+PLTs have an oxygensaturation of less than 15% and a storage partial pressure of carbondioxide of less than 60 mmHg. In an aspect, the OCR-LRpRBC+PLTs have anoxygen saturation of less than 15% and a storage partial pressure ofcarbon dioxide between 20 and 40 mmHg. In an aspect, the OCR-LRpRBC+PLTshave an oxygen saturation of less than 15% and a storage partialpressure of carbon dioxide between 0 and 20 mmHg. In another aspect, theOCR-LRpRBC+PLTs have an oxygen saturation of less than 10% and a storagepartial pressure of carbon dioxide of less than 60 mmHg. In an aspect,the OCR-LRpRBC+PLTs have an oxygen saturation of less than 10% and astorage partial pressure of carbon dioxide between 20 and 40 mmHg. In anaspect, the OCR-LRpRBC+PLTs have an oxygen saturation of less than 10%and a storage partial pressure of carbon dioxide between 0 and 20 mmHg.In other aspects, the OCR-LRpRBC+PLTs has an oxygen saturation of lessthan 5% and a storage partial pressure of carbon dioxide of less than 60mmHg. In an aspect, the OCR-LRpRBC+PLTs have an oxygen saturation ofless than 5% and a storage partial pressure of carbon dioxide between 20and 40 mmHg. In an aspect, the OCR-LRpRBC+PLTs have an oxygen saturationof less than 5% and a storage partial pressure of carbon dioxide between0 and 20 mmHg.

The oxygen reduced leukoreduced packed red blood cells with platelets(OR-LRpRBC+PLT) and oxygen and carbon dioxide reduced leukoreduced wholeblood with platelets (OCR-LRWB+PLT) usually further comprise an additivesolution. Suitable additive solutions according to the presentdisclosure include AS-1, AS-3 (Nutricel®), AS-5, SAGM, PAGG-SM, PAGG-GM,MAP, AS-7, ESOL-5, EAS61, OFAS1, OFAS3, and combinations thereof. In anaspect, the additive solution is added at the time of componentseparation. In an aspect, the additive solution is AS-1. In anotheraspect, the additive solution is AS-3. In other aspects, the additivesolution is SAGM.

The methods and compositions of the present disclosure provide for andinclude the preparation of ‘massive transfusion kits’ (MTKs) havingimproved properties to kits prepared from conventional components. Themassive transfusion kits of the present disclosure can be prepared invarious configurations depending on the clinical needs. The MTKs of thepresent disclosure are stored under oxygen free or oxygen and carbondioxide free conditions until being prepared for use. The OR and OCRconditions can be maintained by sealing in an impermeable enclosureeither with, or without, an appropriate sorbent material. The MTKs ofthe present disclosure may be re-oxygenated prior to use, or useddirectly. In general, the specification provides for massive transfusionkits optimized to deliver RBCs having improved 2,3-DPG levels. Such kitsare prepared from component blood products obtained from oxygen andcarbon dioxide reduced leukoreduced whole blood with platelets(OCR-LRWB+PLT). Alternatively, a kit may be prepared using componentblood products obtained from oxygen reduced leukoreduced whole bloodwith platelets (OR-LRWB+PLT) to produce kits having higher levels ofATP. Kits prepared using the methods of the present specificationprovide platelets suitable for hemostasis together with the oxygenreduced stored red blood cells. Thus, massive transfusion kits of thepresent specification can increase the availability of platelets withoutadditional dilution while further providing RBCs of higher quality(e.g., more deformable, more 2,3-DPG, fewer storage lesions).Importantly, the recovery of blood components from the oxygen reducedwhole blood of the present disclosure increases the availability oftransfusion products for trauma victims and saves and conserves avaluable and limited resource. As discussed above, conventional massivetransfusion kits include a volume of plasma, a volume of pRBCs, andvolume of platelets in a 1:1:1 ratio wherein the amounts of the threecomponents correspond to a unit ‘reconstituted blood’ when transfusedserially or in parallel to a patient in need. Reconstituted blood doesnot directly correspond to whole blood which does not include anadditive solution and has higher levels of anti-coagulant. Furtherreconstituted blood typically includes a larger volume than a typicalunit of whole blood. The reconstituted blood of the present disclosureis improved over the conventional reconstituted blood as it providesadditional platelets in the pRBC fraction (e.g., either oxygen andcarbon dioxide reduced leukoreduced packed red blood cells withplatelets (OCR-LRpRBC+PLT) and oxygen reduced leukoreduced packed redblood cells with platelets (OR-LRpRBC+PLT)). Such cold stored plateletsundergo modification commonly known as platelet storage lesions (PSLs)and cold stored platelets are quickly removed from circulation in thebody. Importantly, cold stored platelets retain the ability to aggregateand have been reported to have increased aggregations and resistance todisaggregation. Accordingly, blood components obtained from the oxygenreduced whole blood of the present specification provide additionalbenefits during trauma transfusion, either alone or in combination withconventional platelets.

The present disclosure provides for, and includes, a massive transfusionkit comprising a volume of oxygen reduced leukoreduced packed red bloodcells with platelets (OR-LRpRBC+PLT) or oxygen and carbon dioxidereduced leukoreduced whole blood with platelets (OCR-LRWB+PLT), orcombinations thereof. In an aspect, a massive transfusion kit provides avolume of plasma and a volume of LRpRBC+PLT. In an aspect, the volume ofplasma and a volume of LRpRBC+PLT is 1:1. In other aspects, the ratio ofplasma to LRpRBC+PLT is between 1:1 and 1:2 by volume. In an aspect, theratio of plasma to LRpRBC+PLT is about 1:2 by volume.

The present disclosure provides for, and includes, massive transfusionkits that include additional platelets together with the plasma andoxygen reduced leukoreduced packed red blood cells with platelets(OR-LRpRBC+PLT) or oxygen and carbon dioxide reduced leukoreduced wholeblood with platelets (OCR-LRWB+PLT).

The massive transfusion kits of the present disclosure provide for avolume of plasma. The plasma of the MTKs can be either fresh plasma orthawed fresh frozen plasma (FFP). The specification provides forobtaining the plasma for MTKs from either conventional sources (e.g.,non-oxygen reduced) or from oxygen reduced or oxygen and carbon dioxidereduces sources. In an aspect, the plasma for an MTK of the presentdisclosure may be obtained from oxygen reduced leukoreduced whole blood(OR-LRWB), oxygen reduced leukoreduced whole blood with platelets(OR-LRWB+PLT), oxygen and carbon dioxide reduced leukoreduced wholeblood (OCR-LRWB), or oxygen and carbon dioxide reduced leukoreducedwhole blood with platelets (OCR-LRWB+PLT). Not to be limited by theory,the plasma obtained from the oxygen reduced sources will have lowerlevels of storage lesions, including for example, lower levels ofcytokines, isoprostane, and microparticles. As provided herein, MTKshaving plasma, platelets and pRBCs according to the presentspecification are provided at a ratio of between 1:1:1 or 1:1:2 byvolume. It will be understood to one of ordinary skill in the art thatthe MTKs of the present disclosure, like conventional MTKs, are designedto provide an equivalent of a unit of blood. It will be recognized thatany arbitrary total volume may be selected while maintaining the recitedratios necessary to be equivalent to reconstituted blood.

EXAMPLES Example 1: Cytokine, Cell-Free Hemoglobin, and IsoprostaneAccumulations in Packed Red Blood Cells During Anaerobic Storage

Fifteen pRBC units are collected from normal healthy donors. Each unitis split and stored as follows: one in standard blood bank conditions(control), the other anaerobically (test) according to methods describedin Yoshida et al., “Anaerobic Storage of Red Blood Cells in a NovelAdditive Solution Improves In vivo Recovery,” Transfusion 49:458-64(2008). At weeks 0, 1, 2, 3, and 6, samples are removed using a sterileconnecting device from the PRBC units. Plasma samples are frozen for thefollowing assays: single batch testing for 22 cytokines using theProcarta Immunoassay Magnetic Bead kit, 8-isoprostane F_(2α) via massspectrometric assay, and cell free hemoglobin via HemoCueplasma/photometer (HemoCue AB, Angelholm, Sweden).

As shown in FIG. 1A, eotaxin reaches a statistically significantdifference at week 2 (86.6 pg/ml-control (c), 64.9-test (t),p-value—0.00213, with statistical significance of p<0.05; day 42 (292-c,112-t; p=0.000). As shown in FIG. 1B, RANTES is different at all timepoints, starting at day 3 (374.6-c, 55.1-t), p-=0.00000; a very largedifference is observed on day 42 (3371.6-c, 88.4-t; p<0.002). As shownin FIG. 1C, differences in cell-free hemoglobin are seen at week 2 (96.0mg/dl-c, 41.7-t), p-=0.00001; day 42 (170-c, 63-t, p=0.0002). As shownin FIG. 1D, storage day 3 shows differences in isoprostane (45.5pg/ml-c, 32.1-t), p=0.00689; day 42 (101.9-c, 64.7-t, p=0.0048).

Example 2: Collection, Leukoreduction and Gas Depletion of Whole Blood

A unit of blood is collected from a donor patient into anticoagulantsolution comprising either CPDA1 or CPDA according to standardprotocols, including collection of heparin tubs. The collected bloodcontaining anticoagulant is leukoreduced according to manufacturer'sinstructions less than or equal to four hours after the initial blooddraw. Baseline ABL90 blood gas and metabolic parameters are determinedfrom the donor heparin tube and the whole blood product according tostandard procedures. See BSL Handbook Procedure BSL-P024: ProcedureManual and Radiometer ABL90 FLEX Gas Analyzer instructions.

An anaerobic control is prepared from each unit of leukoreduced blood bytransferring 120 ml of LRWB/CPDA-1 or LRWB/CPD into a 150 mL transferbag, labeled as appropriate and placed at room temperature (15°-30° C.).

The remainder of the LRWB LRWB/CPDA-1 or LRWB/CPD is processed foroxygen or oxygen and carbon dioxide depletion by transferring to a bloodprocessing bag connected to a Sorin D100 and processed for 5 minutes ata flow rated of 700 ml/minute without gas to generate a BOF processingcontrol. 120 g of the resulting BOF processed blood is transferred to a300 ml transfer bag that has been stored under anaerobic conditions andlabeled BOF processing control. The remainder of the LRWB/CPDA-1 orLRWB/CPD is processed on the Sorin D100 at a peak flow rate of 700ml/minute with a gas flow rate of 3 L/min of a gas compositioncomprising 5% CO₂/95% N₂ until the blood reaches ˜5% SO₂ measuring bloodgas values on a Radiometer ABL90 FLEX Gas Analyzer at 3 to 5 minuteintervals. To reduce carbon dioxide levels, the gas mixture is switchedto 100% N₂ for 1 to 4 minutes until SO₂ reaches 5±1% and pCO₂ reaches30±3 mmHg, monitoring blood gas values every 15-30 seconds to monitordeoxygenation rate. 120 g of the resulting oxygen and carbon dioxidereduced LRWB/CPDA-1 or LRWB/CPD is transferred to a 300 ml transfer bagpreviously stored under anaerobic conditions as described above andlabeled (“C”). Further processing of the LRWB/CPDA-1 or LRWB/CPD isperformed on the Sorin D100 at a flow rate of 700 ml/min with 99% N₂ and1% O₂ until the LRWB/CPDA-1 or LRWB/CPD reaches an SO₂ of 5±1% and pCO₂reaches 7±3 mmHg. 120 g of the resulting oxygen and carbon dioxidereduced LRWB/CPDA-1 or LRWB/CPD is transferred to a 300 ml transfer bagpreviously stored under anaerobic conditions as described above andlabeled (“D”). Additional samples are processed as described above usinga new Sorin D100. Immediately following the preparation of each sample,ABL90 blood gas levels are determined according to manufacturer'sinstructions to establish baseline SO₂ and pCO₂ levels (e.g., T₀). SeeBSL Handbook Procedures. Samples for cytokine analysis are collected andstored at −80° C. for later analysis.

All samples are analyzed as provided below at Example 6.

Example 3: Storage of Anaerobic Test Products

Oxygen reduced and oxygen and carbon dioxide reduced blood in transferbags are wrapped in mesh, secured with elastic and placed in anaerobiccanisters with 4 sorbent sachets (Mitsubishi, SS-300). Canisters aresealed and the canister purged of air using an Alicat Gas ProcessingSystem. See BSL Handbook Procedure BSL-P040: Procedure for Placing BloodProducts in Anaerobic Storage in Canisters. Anaerobic and aerobic bloodis placed in a Blood Bank refrigerator at 1 to 6° C. Canister gauges aremonitored daily to ensure that they read 5±1 psi. Canisters that fallbelow 2 psi are adjusted to standard procedures. See BSL HandbookProcedure BSL-P040: Procedure for Placing Blood Products in AnaerobicStorage in Canisters.

Example 4: Sample Testing

Samples are tested at indicated time points: day zero (T₀) postprocessing, day 1, week 1, week 2, and week 3. Samples may be testedfresh or frozen for later testing as appropriate for a given test. Thetesting includes a complete blood count (CBC), Thromboelastography(TEG).

Prepare platelet rich plasma (PRP) for platelet aggregation immediatelyper manufacturer's instructions.

Perform coagulation screening and additional assays per manufacturer'sinstructions.

Prepare samples for cytokines immediately per manufacturer'sinstructions.

Example 5: ATP Sampling and Measurement

Samples are processed for ATP measurement by deproteinization andprecipitation. 1 ml of sample (e.g., LRWB/CPD or LRWB/CPDA-1 or samplesdescribed above) is precipitated with 1.0 ml ice cold trichloroaceticacid (TCA) (12% w/v) and vortexed for 15 to 30 seconds and incubated onice for 5 minutes. Tubes containing the TCA/Sample mixture arecentrifuged at 3600 g for 5 minutes at 4° C. Samples are immediatelyprocessed to minimize exposure to TCA. The clarified supernate istransferred to a pre-cooled tube and snap frozen on a dry ice alcoholbath and stored at −70° C.

Example 6: Improved Deformability in Stored RBCs that have been StoredUnder Oxygen Reduced Conditions

Nine (9) individual units of whole blood are obtained from healthyconsenting volunteers via a standard 500 mL blood donation. Donatedwhole blood is processed into leukoreduced red blood cell (LR-RBC) unitsaccording to standard AABB/FDA guidelines; the resulting units are thensplit into two halves. One half of the units are O₂ and CO₂ reduced asdescribed in Examples 2 and 3.

The resulting samples are placed in anaerobic, hypothermic storage,while the second half is placed in conventional, aerobic hypothermicstorage. Paired RBC units are stored in a blood bank refrigerator andevaluated weekly for the entire duration of 6-week storage. Prior totesting, the hematocrit of all RBC samples was adjusted to 40% usingnormal saline (0.9% NaCl; RBC-S). The deformability of the RBC-S at thebeginning and during the study is determined as described inInternational Patent Publication No. WO 2013/177339, published Nov. 28,2013. High speed image sequences (˜150 FPS) of the blood samplestraversing artificial microvascular network (AMVN) chip are recorded.The occlusion time, the amount of time flow through the network that isobstructed by non-deformable cells and the frequency at which bloodprofusion through the network is interrupted (occlusion frequency) aredetermined.

Overall bulk perfusion rates through the AMVN system are consistentlyhigher for O₂ and CO₂ controlled blood compared to aerobically storedunits and the total occlusion time is consistently lower for oxygenreduced RBCs (Table 1). These results suggest that reduction of oxygenlevels in LR-RBC units mitigates the deterioration of the biomechanicalproperties of the red blood cell during hypothermic storage.

The oxygen depletion and storage process significantly reduces the rateat which the rheological properties of RBCs deteriorate duringhypothermic storage, and is capable of preserving more physiologicallyrelevant biomechanical properties of the red cells during storage. Theimproved deformability of the RBCs combined with the benefits of wholeblood transfusion indicates that the preserved RBC function will improveretention of RBCs post transfusion, and increased capability oftransfused RBCs to profuse the microvasculature.

TABLE 1 Perfusion rates of Blood Cells After Oxygen Reduced Storage WeekWeek Week Week Week Week Week 0 1 2 3 4 5 6 MMCN O₂ Reduced 203.8 ± 7.4182.3 ± 13.0 167.1 ± 18.2 155.2 ± 12.3 133.2 ± 17.0 131.7 ± 14.1 122.7 ±10.7 perfusion Conventional 200.4 ± 8.5 173.8 ± 10.6 160.0 ± 18.1 142.9± 8.8 122.3 ± 12.2 117.0 ± 12.5 106.2 ± 14.2 rate (pL/s) MMCN O₂ Reduced 18.1 ± 8.5  36.6 ± 7.8  35.4 ± 10.3  45.9 ± 5.1  59.1 ± 8.5  60.1 ± 7.5 63.4 ± 2.1 plugging Conventional  21.3 ± 9.6  41.0 ± 10.0  42.1 ± 13.8 56.5 ± 2.9  67.3 ± 8.8  68.1 ± 7.6  71.3 ± 6.1 event time (%) AMVN O₂Reduced 222.8 ± 12.5 206.7 ± 6.3 200.6 ± 3.5 186.4 ± 6.7 187.0 ± 12.7176.5 ± 13.5 171.4 ± 13.7 perfusion Conventional 220.0 ± 14.9 200.8 ±7.4 194.3 ± 8.8 182.3 ± 3.5 181.8 ± 12.0 171.9 ± 11.2 162.0 ± 11.7 rate(pL/s)

Example 7: Deoxygenation of Platelets does not Impede HemostaticPerformance

Eight (8) units of whole blood (WB) are obtained from healthy consentingvolunteers via a standard 500 mL blood donation. Donated whole blood iscollected in CPDA-1 anticoagulant as described in Example 2 (ResearchBlood Components, Inc.) and leukoreduced with a platelet sparing filter(Imuflex® WB-SP) (LRWB; Terumo Medical Corporation). The resultingfiltered units are then split into two halves. One half of the units areplaced in conventional, aerobic hypothermic storage, while the secondhalf is further divided and placed in anaerobic, hypothermic storage.The anaerobically stored units are oxygen reduced (OR-LRWB) or oxygenand carbon dioxide reduced (OCR-LRWB). The anaerobically stored unitsare processed with the Sorin D100 membrane oxygenator to yield anaerobicunits with about 5% SO₂ and about 35 mmHgpCO₂. The resulting anaerobicunits are placed in standard PVC bags and stored in anaerobic canisterscomprising oxygen sorbent and Nitrogen gas. Paired leukoreduced plateletunits are evaluated weekly for the entire duration of 21 day storage asdescribed below.

The units are evaluated for metabolic parameters including percenthemolysis (Plasma Low, Angelholm Sweden), ATP (DiaSys, Flacht, Germany),and 2,3-DPG (Sigma-Aldrich, St. Louis, Mo.) according to manufacturer'sinstructions. As shown in FIG. 4A, reduced levels of ATP are maintainedin stored OCR-LRWB but increase in stored OR-LRWB compared toconventionally stored LRWB (solid line). As shown in FIG. 4B, increasedlevels of 2,3-DPG were maintained in stored OCR-LRWB and OR-LRWBcompared to conventionally stored LRWB, for up to 21 days. Further, asshown in FIG. 4C, hemoloysis is not significantly changed when comparingstored OR-LRWB and stored OCR-LRWB to conventionally stored LRWB (solidline).

The conventionally stored LRWB and OCR-LRWB are assessed for plasmacoagulation parameters by evaluating Prothrombin Time (PT), activatedPartial Prothrombin time (aPTT), and the levels of Fibrinogen andD-dimer. As shown in FIG. 5 , the aPPT and PT were slightly, but notsignificantly prolonged in conventionally stored LRWB (solid line).Further, no evidence of coagulation activation was observed as evidenceby similar fibrinogen and D-dimer levels.

The conventionally stored LRWB and OCR-LRWB are further assessed forplasma clotting factors by determining the activity levels for factorsV, VIII, protein C activity, protein S activity and von WillebrandFactor (vWF). Protein C and protein S analysis are performed using theACL TOP® (Instrumentation Laboratory) and the STA-R Evolutioncoagulation Analyzer® (Diagnostica Stago, Inc.), respectively, accordingto the manufacturer's instructions. As shown in FIG. 6 , the levels ofFactor V, Factor VIII, Protein C activity, protein S activity, and vWFwere not significantly changed in anaerobic, hypothermic stored OCR-LRWB(broken line) compared to conventionally stored WB (solid line).

The conventionally stored LRWB and OCR-LRWB are further assessed forcoagulation using thromboelastography (TEG) with the HaemoscopeThromboelastograph® analyzer (Haemonetics) according to themanufacturer's instructions. As shown in FIGS. 7A to 7D, no significantdifference was observed for propagation (TEG Angle), amplification (TEGK), maximum amplitude (TEG MA), or reaction time (TEG R) in OCR-LRWB(broken line) compared to conventionally stored LRWB (solid line).

While the present disclosure has been described with reference toparticular embodiments, it will be understood by those skilled in theart that various changes may be made and equivalents may be substitutedfor elements thereof without departing from the scope of the presentdisclosure. In addition, many modifications may be made to adapt aparticular situation or material to the teachings of the presentdisclosure without departing from the scope of the present disclosure.

Therefore, it is intended that the present disclosure not be limited tothe particular embodiments disclosed as the best mode contemplated forcarrying out the present disclosure, but that the present disclosurewill include all embodiments falling within the scope and spirit of theappended claims.

1.-34. (canceled)
 35. An oxygen reduced stored whole blood compositionwith platelets (OR-WB+PLT) for transfusion to a trauma patient in needthereof comprising OR-WB+PLT in an anticoagulant solution, having apre-storage and storage oxygen saturation (SO₂) of 30% or less andstored for a storage period, wherein the stored OR-WB+PLT has one ormore coagulation parameters that are equivalent to or better than thesame one or more coagulation parameters in conventionally storednon-oxygen reduced whole blood with platelets (non-OR-WB+PLT). 36.-48.(canceled)
 49. The oxygen reduced stored whole blood composition withplatelets (OR-WB+PLT) of claim 35, wherein the one or more coagulationparameters are measured by thromboelastography (TEG), wherein the one ormore coagulation parameters are selected from the group consisting ofthromboelastography angle (TEG angle), thromboelastography kinetic value(TEG K), thromboelastography maximum amplitude (TEG MA), andthromboelastography reaction time (TEG R). 50.-88. (canceled)
 89. Theoxygen reduced stored whole blood composition with platelets (OR-WB+PLT)of claim 49, wherein the TEG angle is more than 40°.
 90. The oxygenreduced stored whole blood composition with platelets (OR-WB+PLT) ofclaim 49, wherein the TEG K is between 1 minute to 5 minutes.
 91. Theoxygen reduced stored whole blood composition with platelets (OR-WB+PLT)of claim 49, wherein the TEG MA is between 35 millimeters (mm) to 65 mm.92. The oxygen reduced stored whole blood composition with platelets(OR-WB+PLT) of claim 49, wherein the TEG R is between 4 minutes to 8minutes.
 93. The oxygen reduced stored whole blood composition withplatelets (OR-WB+PLT) of claim 35, wherein the one or more coagulationparameters are selected from the group consisting of prothrombin time(PT), partial thromboplastin time (PTT), fibrinogen level, D-dimervalue, and thrombin generation value.
 94. The oxygen reduced storedwhole blood composition with platelets (OR-WB+PLT) of claim 93, whereinthe PT is between 10 seconds to 15 seconds.
 95. The oxygen reducedstored whole blood composition with platelets (OR-WB+PLT) of claim 93,wherein the PTT is between 32 seconds to 42 seconds.
 96. The oxygenreduced stored whole blood composition with platelets (OR-WB+PLT) ofclaim 93, wherein the fibrinogen level is between 250 milligrams perdeciliter (mg/dL) to 350 mg/dL.
 97. The oxygen reduced stored wholeblood composition with platelets (OR-WB+PLT) of claim 35, wherein thestored OR-WB+PLT has platelet function parameters that are equivalent toor better than platelet function parameters in conventionally storednon-oxygen reduced whole blood with platelets (non-OR-WB+PLT).
 98. Theoxygen reduced stored whole blood composition with platelets (OR-WB+PLT)of claim 97, wherein the platelet function parameters are measured byplatelet aggregometry.
 99. The oxygen reduced stored whole bloodcomposition with platelets (OR-WB+PLT) of claim 35, wherein the storedOR-WB+PLT has a level of a clotting factor that is equivalent to orbetter than a level of the same clotting factor in conventionally storednon-oxygen reduced whole blood with platelets (non-OR-WB+PLT).
 100. Theoxygen reduced stored whole blood composition with platelets (OR-WB+PLT)of claim 99, wherein the clotting factor is selected from the groupconsisting of Factor V, Factor VIII, antithrombin (AT), Protein C, VonWillebrand Factor (vWF), and any combination thereof.
 101. The oxygenreduced stored whole blood composition with platelets (OR-WB+PLT) ofclaim 35, wherein the stored OR-WB+PLT has higher red blood cell (RBC)deformability compared to RBC deformability of conventionally storednon-oxygen reduced whole blood with platelets (non-OR-WB+PLT).
 102. Theoxygen reduced stored whole blood composition with platelets (OR-WB+PLT)of claim 35, wherein the anticoagulant solution is selected from thegroup consisting of citrate-phosphate-dextrose (CPD),citrate-phosphate-dextrose-adenine solution 1 (CPDA-1),acid-citrate-dextrose (ACD), and acid-citrate-dextrose solution A(ACD-A).
 103. The oxygen reduced stored whole blood composition withplatelets (OR-WB+PLT) of claim 35, wherein the trauma patient in needthereof is in need of multiple blood transfusions.
 104. The oxygenreduced stored whole blood composition with platelets (OR-WB+PLT) ofclaim 35, wherein the trauma patient in need thereof is a hemorrhagictrauma patient or a blunt trauma patient.
 105. The oxygen reduced storedwhole blood composition with platelets (OR-WB+PLT) of claim 35, whereinthe storage period is two weeks, three weeks, or more than three weeks.106. The oxygen reduced stored whole blood composition with platelets(OR-WB+PLT) of claim 35, wherein the stored OR-WB+PLT is safe fortransfusion into the trauma patient in need thereof for at least a threeweek period of time.